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ABSTRACT 
 
 
A Synthetic Biological Engineering Approach to Secretion-                                                    
Based Recovery of Polyhydroxyalkanoates  
and Other Cellular Products 
 
by 
 
 
Elisabeth Linton, Master of Science 
 
Utah State University, 2010 
 
 
Major Professors:  Dr. Charles D. Miller and Dr. Ronald C. Sims 
Department:  Biological Engineering  
 
 
The costs associated with cellular product recovery commonly account for as 
much as 80% of the total production expense.  As a specific example, significant 
recovery costs limit commercial use of polyhydroxyalkanoates (PHA), which comprise a 
class of microbially-accumulated polyesters. PHAs are biodegradable compounds that are 
of interest as a sustainable alternative to petrochemically-derived plastics. Secretion-
based recovery of PHAs was studied to decrease PHA production costs. Type I and II 
secretory pathways are commonly used for the translocation of recombinant proteins out 
of the cytoplasm of E. coli.  Proteins were targeted for translocation using four signal 
peptides (HlyA, TorA, GeneIII, and PelB) that operate via type I and II secretory 
machinery. GFP translocation was investigated in parallel due to its relative ease of 
monitoring to gather information about the functionality of signal peptide sequences.  
The translocation of phasin was investigated because of its physical binding interaction 
iv 
 
with the PHA granule surface. Genetic fusion of phasin with targeting signal peptides 
creates a PHA-phasin-signal peptide complex that can then be potentially used for 
cellular export. An important design aspect of this investigation is that synthetic 
biological engineering principles and standardized technical formats BBF RFC 10 and 
BBF RFC 23 were applied for more efficient construction of genetic devices. As an 
additional part of this study, an 
1
H NMR-based PHA quantification method was 
developed to facilitate analysis of intracellular PHAs. Overall, this study demonstrated 
that the BioBrick model can be used to construct functional devices that promote 
secretion of cellular compounds. The information gathered from this work can be further 
optimized and applied to more complex cellular manufacturing systems.  
 
 
(160 pages)
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CHAPTER 1 
 
INTRODUCTION 
 
 
Plastic compounds are heavily used in a variety of applications due to their useful 
material properties and low production costs. However, traditional plastics, such as 
polypropylene and polyethylene, are derived from non-renewable petrochemicals and are 
not readily biodegradable [1]. In 2007, an estimated 31 million tons of non-degradable 
petrochemical plastic materials were disposed of in the United States in the form of 
municipal solid waste [2]. In response to landfill accumulation of this plastic waste, 
efforts have increased to reduce plastic consumption, to expand recycling programs, and 
to improve waste management technologies, such as pyrolysis and composting [3-4]. 
However, these methods do not provide an economical and complete waste management 
solution [1, 3]. Additionally, the use of non-renewable fossil fuels for plastic production 
remains an issue. The pervasive use of petroleum-based plastic compounds reinforces a 
need for sustainable bioplastic alternatives [1].  
Polyhydroxyalkanoates comprise a class of polyesters accumulated by a variety of 
microorganisms [5-7]. These bioplastic compounds are intracellularly accumulated and 
stored in response to an environmental stress or nutrient limitation as a reserve of carbon, 
energy, and reducing power [5, 7-9]. PHAs have comparable material properties to 
conventional plastics, like polypropylene, but are fully biodegradable and renewable [6, 
10]. As a result, PHAs are of particular interest as a sustainable source of non-
petrochemically-derived thermoplastics for use in an assortment of commercial and 
medical applications [1, 9]. 
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High costs of PHA production have limited widespread application of the 
bioplastic [3, 6-7, 11-12]. Reported economic analyses for various industrial production 
systems have placed the cost of PHAs at $2.65-5/kg [11-14]. In contrast, 
petrochemically-derived plastics cost about $1.57-1.67/kg for high-density polyethylene 
and $2.11-2.18/kg for polypropylene [15]. This discrepancy in expense is largely 
attributable to carbon source and downstream processing costs [16]. Although some 
progress has been made to minimize these expenses, the overall cost of PHA has not yet 
been sufficiently reduced for economical production.  
Downstream processing is commonly the most expensive aspect of PHA 
production. It is estimated that extraction and purification costs represent as much as 50% 
of the total process expense [17]. Traditional PHA downstream processing methods 
requiring the use of solvents, enzymatic digestion, or mechanical disruption are 
expensive and impractical for industrial-scale recovery [17]. Over the years, a variety of 
PHA recovery methods have been developed, although none of these techniques have 
resulted in significant economic improvements [18]. Accordingly, further research and 
development of new methods for PHA recovery is necessary. 
A secretion-based mechanism holds potential to simplify PHA recovery by 
eliminating the need for chemical or mechanical disruption of cells. PHA-associated 
proteins, called phasins, are known to bind tightly to the PHA granule surface [19-20]. As 
a result of this interaction, this project will investigate the possibility of recovering PHA 
indirectly by tagging the phasin protein for translocation. Specifically, appending a signal 
peptide to a recombinant protein promotes export of the protein out of the cytoplasm 
[21]. The interaction between phasin and PHA is of interest for granule recovery because 
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PHA is a non-proteinaceous compound and, consequently, the signal peptide cannot be 
directly attached to PHA granules. The phasin protein with a fused signal peptide would 
bind to PHA granules, thereby creating a PHA-phasin-signal peptide complex that may 
be recognized by the cell for export.  
The size of PHA granules or other properties may inhibit efficient translocation 
across cellular membranes [22]. Under these circumstances, secretion of phasin protein is 
a valuable discovery as it provides foundational information on how to alter and optimize 
the system to better promote PHA export. The secretion of GFP was examined first due 
to the relative ease with which the fluorescent protein can be monitored [23-24]. Studying 
the behavior of GFP under the influence of various signal peptides provides valuable 
information that can be applied to studying phasin expression and recovery. Synthetic 
biological engineering techniques and standard biological parts, called BioBricks, were 
used to carry out this study. The purpose of using this standardized biological format was 
to simplify the construction of different composite devices from a few individual 
BioBrick parts and to create parts that can be used directly in other studies for protein 
secretion.  
 
Hypotheses 
  This research was conducted in order to obtain foundational information for 
secretion-based recovery of cellular products using synthetic biological engineering 
methods. The hypothesis of the overall, long-term study is summarized in three parts: 
1. A trial-and-error synthetic biological engineering approach using several different 
signal peptides will lead to membrane translocation of GFP.   
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2. The signal peptide information obtained from studying GFP will provide a 
foundation for constructing systems for cellular export of phasin.  
3. The interaction between phasin and PHAs can facilitate secretion-based bioplastic 
recovery. 
 
Objectives  
 
The overall objective of this study is to investigate ways to use synthetic 
biological engineering to recover cellular products via secretion, and to potentially 
recover bioplastic through a phasin/PHA interaction. More specific project objectives 
include: 
1. Design and construct a BioBrick library of signal peptides, phasin, and GFP parts, 
as well as composite devices for investigating secretion 
2. Test the functionality of BioBrick devices in Escherichia coli 
3. Monitor the translocation of GFP using microscopy, SDS-PAGE and western 
blotting 
4. Determine efficient methods for detecting and measuring intracellular PHA 
accumulation 
5. Produce phasin and PHAs in E. coli and construct systems for PHA secretion 
The completion of the outlined objectives would contribute novel information to 
PHA research. Investigating the secretion of phasin protein would provide a foundation 
for further study and optimization of PHA recovery. Additionally, this project will 
produce genetic devices and methods that can be employed in similar studies on PHA or 
recombinant protein recovery. 
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Thesis Outline 
 
Chapter II provides a comprehensive review of PHAs, recombinant protein 
translocation, and synthetic biological engineering. Chapter III describes the design and 
results of the GFP translocation process. Chapter IV details the developed 
1
H NMR 
procedure for quantifying and identifying intracellular PHAs. Chapter V describes phasin 
and PHA production in E. coli, as well as the genetic systems constructed for compound 
translocation. Chapter VI summarizes general conclusions for the entire study. Chapter 
VII provides some insight on potential future directions for product recovery studies.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
 
PHA Biosynthesis 
PHAs are a class of naturally accumulated biodegradable plastic compounds [1-
3]. These bioplastics have material properties comparable with commodity plastics, like 
polypropylene, and could serve as a renewable and sustainable commercial substitute for 
fossil-derived polymers [2, 4-6]. Additionally, high PHA compatibility with human 
systems has led to use in a range of medical applications, such as orthopedic materials 
and sutures [4, 6-9]. 
PHAs are classified into three categories based on the number of carbon atoms in 
the monomer unit [10]. Specifically, SCL-PHAs consist of 3-5 carbon atoms and are the 
most extensively studied group of PHAs [11].  Of SCL-PHAs, PHB is the most 
commonly studied. Variation in PHA chain length is a function of the organism, the 
metabolic pathway, and the available substrate [1, 5-6, 12]. The material properties of the 
polymer can be adjusted through the formation of PHB copolymers [13]. For example, 
copolymers of PHB and other SCL-PHAs like PHV are formed in the presence of volatile 
fatty acids, such as propionate and acetate [14-15]. The elasticity of the polymer 
increases with an increasing proportion of hydroxyvalerate monomers [11]. 
PHB synthesis from acetyl coenzyme A (acetyl-CoA) occurs by three enzymatic 
reactions [11, 16]. In the first step, 3-ketothiolase combines two molecules of acetyl-CoA 
to produce acetoacetyl-CoA. The acetoacetyl-CoA molecules are reduced by NADPH-
dependent acetoacetyl-CoA reductase to form 3-hydroxybutyryl-CoA (3HB-CoA). 
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Lastly, 3HB-CoA molecules are polymerized with an existing PHB polymer by the action 
of PHB synthase [11]. The biosynthetic genes that code for 3-ketothiolase and 
acetoacetyl-CoA reductase are PhaA and PhaB, respectively [11]. The structure of the 
PHB synthase component varies between different bacteria and cyanobacterial species. In 
Cupriavidus necator (formerly Ralstonia eutropha), the PHB synthase is coded for by 
PhaC [3]. Metabolic pathways for bioplastic production are given as Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 The metabolic pathway for PHA biosynthesis in C. necator from propionic 
acid and glucose carbon sources.  
 
In the presence of excess exogenous carbon source, heterotrophic organisms like 
C. necator and Azotobacter vinelandii can accumulate PHAs in excess of 80% (w/w) [3-
4, 17]. Photosynthetic organisms, like cyanobacteria and Rhodobacter species, are also 
capable of producing PHA [18-20].  However, PHA production rates in these organisms 
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are low in comparison to heterotrophic species, particularly in the absence of exogenous 
carbon sources like acetate or fructose [20-21].  
Recombinant E. coli harboring the PHA synthesis machinery of C. necator can 
accumulate PHB in excess of 90% (w/w) [22]. E. coli have much higher growth rates 
than their photoautotrophic counterparts, and are also more readily engineered for 
enhanced production [23-24]. PHA production in E. coli is not naturally regulated by the 
cell, and can therefore be controlled [24]. For example, constitutive production of PHA is 
not efficient for the cell due its negative effect on cellular growth. The use of a well-
regulated promoter, such as the lac or tac promoters, provides the user with the control to 
optimize the point of PHA production. After sufficient cellular growth, the addition of 
IPTG converts the lac repressor (LacI) into its inactive form, thereby allowing for 
transcription of the PHA operon to take place [25].  
 
Current Methods for PHA Recovery 
 
Recovery of cellular products is often a difficult and expensive challenge. It is 
estimated that as much as 80% of protein production costs are attributable to downstream 
processing [26]. Likewise, the separation and purification cost for non-protein products, 
like PHAs, are significant and commonly represent more than half of the total process 
expense [27].   
The oldest methods for PHA recovery are based on disruption of the cellular 
membrane by the addition of chemicals [28]. Variations on these methods have been 
developed, which involve the use of different chlorinated [29], liquid halogenated [30], 
and non-halogenated solvents [31]. Cellular digestion methods using surfactants (SDS), 
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NaOCl, or combinations of these chemicals have also been extensively studied [32-33]. A 
common method for PHA recovery uses NaOCl to digest the cells and chloroform to 
dissolve and recover PHA [33]. 
Mechanical cell disruption for PHA recovery is categorized as either solid shear 
or liquid shear [28]. Solid shear methods involve the use of a bead mill to grind the cells, 
while high pressure homogenization is an example of liquid shear disruption [28]. Newer 
methods, like dissolved air flotation or selective dissolution of cellular mass [34], are also 
investigated and could lead to reduced costs [28]. 
Genetic engineering strategies have also been used in an effort to simplify PHA 
recovery. Recombinant E. coli MG1655 harboring PHA biosynthesis genes from C. 
necator was used to instigate spontaneous autolysis of the cell [27]. Up to 80% of the 
cells in culture released PHA granules, which were subsequently recovered by 
centrifuging and washing with distilled H2O [27]. Another method used recombinant 
PHA-producing E. coli transformed with the E-lysis gene of bacteriophage PhiX174 from 
plasmid pSH2 for recovery [35]. In this system, amorphous PHB is pushed out of the cell 
through an E-lysis tunnel structure, which is an opening in the cell envelope [35]. The 
osmotic pressure difference between the cytoplasm and the culture medium provides the 
driving force for PHA movement into the extracellular medium. PHA is then recovered 
by centrifugation or through the addition of divalent cations [35]. These lysis methods 
eliminate the need for chemical or mechanical means for cellular disruption, but result in 
cell death and fail to promote a continuous PHA production system.  
Extracellular deposition of PHA granules was observed in a mutant strain of 
Alcanivorax borkumensis SK2, which is a marine bacterium that uses hydrocarbons as its 
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source of carbon and energy [36]. This is the first account of PHA accumulation outside 
of a cell [37]. However, the mechanism by which this deposition occurs is unknown [36-
37]. A defined system for PHA excretion has yet to be created. Such a system would be 
of value due to the ability to optimize and introduce the mechanism into other organisms 
with advantageous characteristics, such as fast-growing E. coli or photoautotrophic PHA-
producers like R. sphaeroides and Synechocystis PCC 6803. 
Secretion of products to the culture medium means that mechanical or chemical 
cellular disruption is not required for recovery, which could lead to a continuous PHA 
production system. Various factors may inhibit PHA export to the extracellular medium. 
In this scenario, PHA translocation to the periplasm would still be beneficial because 
osmotic shock or cell wall permeabilization techniques can be used for simplified 
recovery [38-39]. 
 
Recombinant Proteins 
 
Phasin 
 
Phasin is a low-molecular weight protein that plays a role in PHA granule 
formation by binding to the PHA granule surface [40-42]. The specific purpose of phasin 
production is not completely understood [43], although some effects of the phasin/PHA 
interaction have been determined. It has been demonstrated that the production of phasin 
is dependent on PHA accumulation [41]. Specifically, it is suggested that phasin 
expression requires the presence of an active PHA synthase and that the interaction 
between these two proteins promotes PHA synthesis [41]. 
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It was observed that the level of PHA accumulation substantially decreases and 
the size of PHA granules increases when phasin is either absent or regulated by a 
repressor, PhaR [42].  Therefore, PHA production levels are enhanced in the presence of 
phasin due to an increased granule surface-to-volume ratio [42, 44]. In addition to 
reducing PHA granule size, other functions of phasin have been proposed. In the absence 
of phasin, other proteins are able to bind to the granule surface [42]. Therefore, phasin 
may function to inhibit attachment of other proteins to the PHA surface that could cause 
defects in granule formation [42, 44]. 
The interaction between phasin and PHB has been exploited for recombinant 
protein purification by affinity binding [45]. In this system, a recombinant protein 
product, a self-splicing element called an intein, and phasin are genetically fused [45]. 
The fusion protein complex is produced in PHB-accumulating E. coli [45]. The phasin 
protein binds to the surface of the PHB granule, and a cleavage-inducing buffer 
stimulates the release of the product protein into the soluble fraction of the solution [45]. 
For this procedure, PHB is released and proteins are recovered only after the cell is lysed, 
which is not ideal. However, the system provides evidence that the phasin/PHA 
interaction is strong and that genetic fusion of other elements with phasin does not inhibit 
binding to PHA.  The fusion of phasin with a targeting signal peptide could therefore 
result in a signal peptide/phasin/PHA complex that is recognized by a cell for 
transmembrane export. 
Efficient recovery of PHA granules via secretion of a signal peptide/phasin/PHA 
complex may be inhibited due to the size of PHA granules. The molecular mass of PHAs 
varies from about 50 kDA to 1,000 kDA based on the growth parameters and host strain 
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used [5]. However, the binding of phasin decreases the molecular weight of PHA and 
encourages its formation as numerous, small granules [42]. Specifically, small granules 
of PHA approximately 20 – 60 nm in diameter accumulate in the presence of phasin and 
absence of the PhaR repressor, as shown in Figure 2.2 [42].  This indicates that 
enhancement of phasin expression could further reduce granule size, which may make 
PHAs more suitable for translocation. Further testing to determine the strength of the 
binding interaction and to optimize PHA granule size would be necessary in a 
phasin/PHA secretion-based system. 
 
 
 
 
 
 
 
Figure 2.2 The effect of PhaR and PhaP on granule size [42]. The bar represents 0.5 µm. 
 
Green Fluorescent Protein 
GFP is a naturally-occurring fluorescent protein originally discovered in 
Aequorea victoria [46].  Since its discovery, GFP has been used for many applications, 
including gene expression studies, fusion protein construction, and cellular labeling and 
sorting [47].  Many organisms, including most notably yeast and E. coli, are capable of 
GFP expression [48]. 
The tertiary structure of GFP is represented as a β-barrel, with the chromophore in 
the center [47].  GFP consists of 239 amino acids and has a molecular weight of 26,870 
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Daltons [49]. The chromophore of the protein absorbs ultraviolet light at about 395 nm to 
excite electrons to a higher energy state. A green light is emitted at about 509 nm when 
these electrons move to a lower energy state [47].   
The fluorescence photostability and usefulness of GFP as a practical reporter have 
been improved through various mutations of the original protein.  The cycle 3 mutant is 
of special interest because it produces a fluorescence signal 18-fold greater than wild-
type GFP [50-51].  The cycle 3 mutant contains three point mutations of amino acids 
found in the β-sheets of the protein. Specifically, amino acids phenylalanine100, 
methionine154, and valine164 were mutated to serine, threonine, and alanine, 
respectively [50]. These mutations improve the characteristics of GFP by discouraging 
the formation of inclusion bodies by increasing the hydrophilicity of the molecule [50].  
GFP is an ideal candidate for fusion studies because amino- or carboxy-termini 
fusions with GFP typically do not inhibit fluorescence [48].  For example, active and 
folded GFP is translocated into the periplasm of gram-negative bacteria after fusion with 
TAT-dependent TorA signal peptide [52-54]. Due to its ease of detection, GFP was 
studied in parallel with phasin secretion to provide a framework for determining 
efficiency and functionality of targeting sequences. 
 
Principles of Secretion in Gram- 
Negative Organisms 
 
The functionality of protein secretion mechanisms is affected by the structural 
differences between gram-positive and gram-negative organisms [55-56]. Gram-positive 
species have a solitary cytoplasmic membrane. This effectively means that membrane 
translocation is equivalent to secretion in these species [55].  Alternatively, gram-
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negative organisms have both an inner and outer membrane that proteins must cross in 
order to be fully secreted.  Accordingly, proteins can either be exported into the 
periplasmic space or secreted into the extracellular medium [57]. The following sections 
discuss protein secretion pathways in gram-negative organisms.  
 
Secretion Pathways 
 
There are six pathways for recombinant protein secretion in gram-negative 
prokaryotes, numbered I through VI [38, 55]. While these pathways differ, they each 
promote secretion while maintaining the integrity of the cellular structure [58]. Types I 
and II are the most common pathways for recombinant protein secretion [38] and will be 
discussed here.  
Type I secretion is a single-step translocation of protein across both the inner and 
outer membranes [59]. A commonly discussed example of type I secretion is the 
hemolysin system [60]. The constituents of this system include inner membrane proteins 
HlyB and HlyD, as well as the TolC outer membrane protein [60]. These three proteins 
interact to form a channel that spans the periplasm [38]. Appending the last 42-60 amino 
acids of the C-terminus of HlyA protein to the C-terminus of a recombinant protein 
targets the protein for secretion [61-63]. The HlyA signal sequence binds to the channel 
complex, resulting in ATP hydrolysis by HlyB to drive protein secretion [61]. Proteins as 
large as 4000 amino acids can be secreted through the type I channel, which has an 
internal diameter of 3.5 nm and a length of 14 nm [64-65].  Unlike in the type II pathway, 
the signal peptides of type I secretion remain attached to the protein after export out of 
the cytoplasm [38].  The type I secretion system is depicted in Figure 2.3. 
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Figure 2.3 The type I hemolysin secretion system [38]. 
 
The type II secretion pathway is a two-step process. The cytoplasmic protein must 
first be exported into the periplasm through the action of a translocase [38]. Specifically, 
the Sec and TAT machinery facilitate protein movement across the inner membrane and 
will be discussed in detail in the next section.  After entering the periplasm, translocation 
of the protein into the extracellular medium is carried out by a secreton (or secretin), 
which is a 12-16 core protein complex present in many gram-negative strains, including 
E. coli K-12 [58, 66].  Although the secreton functionality is not completely documented, 
it is known that protein conformational changes are necessary for this process to be 
carried out [38, 58, 67]. 
Translocation of cellular products into the periplasm is advantageous over 
cytoplasmic production because recovery of periplasmic products is relatively simpler 
[38]. There are additional mechanisms for recovering periplasmic proteins if the secreton 
machinery is either not present in the host strain or incompatible with the protein of 
interest. These mechanisms are depicted in Figure 2.4. L-form and Q-cells are mutant 
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strains that have a weakened outer membrane, allowing for proteins to leak into the 
extracellular medium [38].  However, these organisms have reduced growth rates and are 
not ideal candidates for general cellular production.  The permeability of the outer 
membrane may be enhanced mechanically, such as by application of ultrasound, or 
through chemical treatment by addition of Triton X-100 or 2% glycine [68]. As another 
example, enzymatic digestion with lysozyme breaks the outer membrane to release 
periplasmic proteins [39]. Another alternative involves coexpression of genes, such as kil, 
out, and tolAIII, that cause cellular lysis and subsequent release of recombinant proteins 
[38, 68]. The downside to these alternatives is the weakening of cell integrity. 
 
 
 
 
 
Figure 2.4 Methods for recovering proteins from the periplasm [38]. 
 
 
Cytoplasmic Membrane Translocation  
Several membrane-associated components mediate translocation of proteins 
across the inner membrane of gram-negative E. coli [69]. This machinery includes 
translocases, ATPases, and accessory proteins [69-70]. The Sec and TAT systems are the 
two general mechanisms by which proteins are transported into the periplasm, with the 
Sec-translocon providing the most common export route [69-70]. Within the Sec 
category, proteins are exported either via the SecB-dependent pathway or by the action of 
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the signal recognition particle (SRP) [38]. The attachment of a short sequence, called a 
signal peptide, to the N-terminus of a protein is generally necessary for targeting proteins 
to any of these translocation pathways [38, 68-69].   
In the Sec pathway, SecA is attached peripherally to the inner membrane and 
drives peptide translocation through ATPase activity [71].  Integral membrane proteins 
SecY and SecE form the core of the Sec translocon, and SecG interacts with this core to 
form a multimeric protein complex, SecYEG [70]. This complex functions as a protein-
conducting channel for both post-translational and co-translational protein export [69-70]. 
Interestingly, the SecYEG translocon can be found in all domains of life, reiterating the 
prevalence and importance of this mechanism for protein export [72].  
A SecB-dependent mechanism is used by gram-negative species to target post-
translational periplasmic and outer membrane proteins to the Sec-translocon [69]. Of the 
three translocation routes, the SecB-dependent pathway is the most common for 
recombinant protein export [38]. First, a trigger factor binds to the preprotein as it leaves 
a ribosome [38, 69]. Next, the unfolded protein is recognized and bound by the SecB 
chaperone protein and directed to SecA, where ATP hydrolysis provides the energy to 
move the protein through the SecYEG translocase into the periplasm [38]. In co-
translational protein export, a signal recognition particle (SRP) identifies and interacts 
with the signal sequence of the nascent protein as it is exiting the ribosome to the Sec-
translocon [38, 69, 73].  
The TAT system is used to export folded proteins into the periplasmic space [68].  
Like the Sec-dependent pathways, specific N-terminal signal peptide sequences target a 
protein for export by the TAT machinery. Although similar, TAT signal peptides differ 
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from those that target proteins to the Sec machinery. TAT signal peptides contain a 
conserved sequence of seven amino acids, (S/T)-R-R-x-F-L-K, at the interface between 
the N- and H-regions, where x represents a polar amino acid [74-75]. The twin-arginine 
residues are consistently found in TAT signal peptides, and the occurrence of the other 
amino acids in the conserved sequence is greater than 50% [74-76]. 
Whether a protein is targeted to the SecB, SRP, or TAT pathway is largely 
dependent on the characteristics of the attached signal peptide [38, 69, 71]. For example, 
the hydrophobicity of the signal peptide plays a role in designating which route will be 
used for protein export [69, 74]. The affinity of a signal sequence to the SRP increases 
with the number of hydrophobic residues in the H-domain of the signal peptide [77]. 
Lastly, TAT pathway signal peptides are the most hydrophilic in the H-domain [74]. 
Moreover, increasing H-domain hydrophobicity of TAT signal sequences can even divert 
a protein typically translocated via the TAT pathway to the Sec translocon [74, 78].  The 
sequence of the mature region of the protein can also affect pathway targeting, 
particularly in regard to the SecB mechanism [69]. The initial step of the type II secretion 
mechanism is provided as Figure 2.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Protein translocation via type II Sec- and TAT-dependent secretion. 
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Signal Peptides 
Signal peptides consist of about 15-30 amino acids and are generally required to 
direct a secretory protein to the translocons of the cytoplasmic membrane [57, 68-69]. 
Despite overall sequence variability, structural similarities exist between different signal 
peptides, including a positively-charged 2-10 amino acid N-region, a hydrophobic core 
H-region, and a neutral C-domain of about 6 residues [57, 74, 79].  The C-domain 
conforms to the -3, -1 rule in which amino acids with short and neutral side-chains, such 
as alanine, are required in positions -3 and -1 of the sequence [68, 73]. A signal peptidase 
interacts with a cleavage recognition site within the C-domain to release the protein into 
the periplasmic space [68-69]. The absence or mutation of the cleavage site can lead to 
the targeted protein remaining fixed to the inner membrane [69]. 
The signal peptide is typically necessary for all translocation pathways. However, 
certain protein-coding sequences can be secreted without having an attached signal 
peptide due to the presence of additional targeting information within the sequence [69]. 
Additionally, an attached signal sequence does not guarantee export of a protein, which 
further suggests that information in the protein sequence itself can affect secretion 
efficiency [69]. However, there are many reported examples of recombinant protein 
translocation by gene fusion with a signal peptide. For example, fusion with the TAT 
substrate trimethylamine-N-oxide (TMAO) reductase signal peptide TorA resulted in the 
export of folded GFP into the periplasm of E. coli [52-54, 75].  
Two factors that affect protein export are the positive charge of the N-terminus of 
the signal peptide and the charge of the N-terminus of the recombinant protein [80]. It has 
been determined that increasing the positive charge of the signal peptide N-terminus not 
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only enhances the interaction with SecA protein, but also reduces the requirements of 
SecA ATPase activity for translocation [80].  Therefore, a higher net positive N-terminus 
charge improves the rate of protein translocation [38]. For the recombinant protein, the 
charge of the N-terminus also affects protein secretion. A net positive charge within the 
first five amino acids near the C-domain cleavage site of the signal peptide can reduce 
protein export by as much as 50-fold because the charge inhibits the protein from 
entering the lipid bilayer [81].  
Although factors like hydrophobicity and charge are known to affect protein 
export, there are few available guidelines for selecting a proper signal peptide for any 
given protein [68]. It is therefore appropriate to investigate recombinant protein secretion 
by trial-and-error with different signal peptides [68].  The mechanisms of protein 
secretion are complicated and many obstacles can inhibit the process. Some commonly 
observed problems include incomplete translocation, degradation of recombinant protein 
by proteases, formation of inclusion bodies, and inefficiency of secretion machinery [38, 
68]. Optimization of secretion efficiency requires balancing the promoter strength and 
gene copy number so as not to overwhelm the system [38]. Lastly, some proteins may 
simply be unsuitable for secretion due to their size or sequence [58]. 
 
Synthetic Biological Engineering  
The BioBrick Standard 
The aim of synthetic biological engineering is to simplify the process of 
genetically modifying biological systems [82]. Specifically, the BioBrick standard was 
created in an effort to provide a defined set of guidelines for engineering biological 
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systems [83]. This standard aims to eliminate much of the guesswork in genetic 
engineering and encourage more extensive collaboration through creation of a repository 
for genetic parts [83].  
A BioBrick refers to a natural nucleic acid sequence that has been obtained and 
refined in such a way that it follows defined criterion [82]. The original BioBrick 
technical standard (BBF RFC 10) is characterized by a DNA sequence flanked by a 
prefix of EcoRI and XbaI restriction sites and a suffix of SpeI and PstI [83]. The 
sequence with prefix and suffix is then inserted into a circular, double stranded DNA 
vector that contains an origin of replication site and a region coding for antibiotic 
resistance [83]. Individual BioBrick parts can then be combined to create functional 
composite devices by digestion with different combinations of restriction enzymes and 
ligation of parts. For example, digestion of a BioBrick part with EcoRI and XbaI creates 
a hole in which a part digested with EcoRI and SpeI can be inserted.  SpeI and XbaI sites 
are compatible and form a scar upon religation. To conform to the BioBrick standard, the 
four restriction enzyme sites present in the prefix and suffix cannot be found at any other 
point within the sequence [83].  
The motivation for the development of a biological standard was in part provided 
by standardized systems used in other fields, such as in uniformity of screw threads, 
gasoline formulations, and units of measure [84]. BioBrick parts manufactured by other 
researchers can be obtained from the Massachusetts Institute of Technology Registry of 
Standard Biological Parts [85]. This infrastructure facilitates more extensive 
collaboration and minimizes repetitive construction of similar parts. 
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The BioFusion Standard 
The Silver fusion (BioFusion) standard (BBF RFC 23) was created in 2006 to 
support genetic fusion of parts using the BioBrick standardized assembly method [86]. 
The original BioBrick standard does not facilitate genetic fusion because the mixed site 
formed upon ligation of two parts is eight base-pairs in length and contains a stop codon, 
TAG [86]. These two factors inhibit genetic fusion of proteins. As an alternative, the 
BioFusion standard uses a slightly modified prefix and suffix sequence conducive to 
genetic fusion, but still retains compatibility with the original BioBrick technical standard 
[86]. As seen in Figure 2.6, a single nucleotide is eliminated from both the prefix and 
suffix in BioFusion. This alteration results in a six base-pair scar that does not contain a 
stop codon [86]. Other technical standards have recently been developed to allow for 
BioBrick fusion [87]. However, these standards are incompatible with the original 
BioBrick technical standard [87]. 
 
 
 
 
Figure 2.6 BioFusion prefix and suffix and the mixed site when XbaI and SpeI are 
combined. The scar formed upon religation is compatible for genetic fusion [86]. 
 
There are several factors that must be taken into account when using the BioBrick 
system. For example, the scar formed by combining two BioFusion compatible parts 
contains an arginine amino acid, which possesses a strong positive charge [86]. This 
charge may negatively affect the folding of proteins or secretion of proteins. Furthermore, 
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factors like plasmid copy number, antibiotic resistance, and origin of replication can 
affect protein expression. For example, the pMB1 origin of replication found in many of 
the BioBrick vectors is incompatible with the ColE1 replicon [88].  
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CHAPTER 3 
 
TRANSLOCATION OF GREEN FLUORESCENT PROTEIN USING A  
 
SYNTHETIC BIOLOGY APPROACH WITH  
 
MULTIPLE SIGNAL PEPTIDES
1
 
 
 
Abstract 
 
Background  
Type I and II secretory pathways are commonly used for the translocation of 
recombinant proteins out of the cytoplasm of E. coli.  The purpose of this study was to 
evaluate four signal peptides (HlyA, TorA, GeneIII, and PelB), representing the most 
common secretion pathways in E. coli, in their ability to target GFP for membrane 
translocation.  An important design aspect of this investigation is that synthetic biological 
engineering principles and standardized technical formats BBF RFC 10 and BBF RFC 23 
were applied for the construction of signal peptide-GFP fusion devices. 
 Results 
It was determined that the HlyA signal peptide targets GFP for secretion to the 
extracellular media via the type I secretory pathway, whereas TAT-dependent signal 
peptide TorA and Sec-dependent signal peptide GeneIII exported GFP to the periplasm. 
Conclusions  
The use of biological technical standards simplifies the design and construction of 
signal peptide-recombinant protein genetic devices. These parts are functional in 
targeting proteins for membrane translocation via type I and II secretion mechanisms in 
E. coli.  The utility of the standardized parts model is further illustrated because 
1  
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biological parts constructed for this study can be directly applied to other studies on 
recombinant protein secretion.  
 
Background 
 
Translocation of recombinant proteins to the extracellular medium or periplasmic 
space of gram-negative bacteria is advantageous for a number of reasons. For example, 
secretory production can lead to enhanced protein stability, improved yields of active 
proteins, and minimized downstream processing requirements [1-4]. The purposes of this 
study were to demonstrate both periplasmic translocation and extracellular secretion of 
green fluorescent protein (GFP) through comparative analysis of multiple signal peptides 
and to determine whether synthetic biological engineering technical standards can be 
effectively implemented to construct these systems. 
Escherichia coli is commonly used for recombinant protein expression due its 
rapid growth rate and ability to express high levels of foreign protein [1, 4-5]. 
Consequently, understanding the secretory mechanisms of this organism is of particular 
importance. Of the six secretory pathways described for gram-negative bacteria [6-9], 
type I and type II secretion are most commonly employed for recombinant protein 
translocation in E. coli [2, 10]. Type I and II secretion mechanisms and examples of their 
use have been previously reviewed in detail [2, 10-12].   
Type I secretion is a single-step translocation of targeted proteins across both the 
inner and outer membranes to the extracellular milieu [7, 13]. The type I mechanism is 
described as the simplest of all gram-negative secretory pathways, and its proteinaceous 
constituents include an outer membrane protein, a membrane fusion protein, and an ABC 
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transporter [7, 14]. Secretion of α-hemolysin is an example of the type I mechanism and 
involves HlyB and HlyD inner membrane proteins and TolC outer membrane protein [15-
17]. The hemolysin system is naturally present in pathogenic E. coli [14], although TolC 
is found in K-12 and B strain genomes.  
Unlike type I secretion, the type II secretory pathway targets proteins to the 
periplasmic space [2, 18]. Periplasmic proteins can then be recovered by mechanically or 
chemically increasing the outer membrane permeability [2, 19], coexpressing genes for 
lysis of outer membranes [2], or by the action of a 12-16 core protein secreton (or 
secretin) complex [10, 12, 20-21]. Type II translocation of proteins across the inner 
membrane of E. coli is mediated by either Sec or TAT cellular machinery, with the Sec-
translocon providing the most common export system [18, 22-23]. The SecYEG 
multimeric protein complex functions as a protein-conducting channel for both post- and 
co-translational protein export [18, 23-24], whereas the TAT system exports fully-folded 
proteins into the periplasmic space [2, 25].   
Appending a short signal peptide sequence to the C- or N-termini of a protein is 
typically required to target proteins to the type I and II secretory pathways [2, 10, 23, 26].  
Many commonly used signal peptides are derived from natural secretory proteins, like 
alkaline phosphatase and outer membrane protein A [5]. Recombinant type I secretion is 
accomplished by fusing the last 46-60 amino acid residues of the C-terminus of HlyA 
protein to the C-terminus of a protein [27-30]. Upon secretion, the signal peptide remains 
attached to the recombinant protein [17, 31]. For the type II pathway, protein targeting is 
carried out through N-terminal fusion of signal peptides [2]. Most type II signal peptides 
are 18-30 amino acids in length and consist of a positively-charged 2-10 amino acid N-
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region, a hydrophobic core H-region, and a neutral C-domain of about 6 residues [32-35]. 
Whether a protein is targeted to the TAT or Sec machinery is largely a function of signal 
peptide characteristics, like hydrophobicity [23, 34, 36].  
Due to its ease of detection, GFP is a popular reporter protein for studying 
biological systems [37-38] and is useful for evaluating signal peptide response. 
Translocation of active GFP in E. coli has been achieved by the TAT pathway through 
fusion with trimethylamine-N-oxide (TMAO) reductase TorA signal peptide [39-42] and 
with the FliP signal peptide [43]. In addition to E. coli, Gram-positive organisms [44], V. 
anguillarum [45], Chinese hamster ovary cells [46], and Synechococcus PCC 7942 [47] 
are all capable of GFP translocation. Unlike these previous studies, a number of signal 
peptides representing multiple pathways were evaluated. To our knowledge, translocation 
of GFP to the extracellular medium by type I secretion in E. coli has yet to be 
demonstrated. Additionally, BioBrick technical standards have not been previously used 
to construct type I and II secretory mechanisms for GFP translocation.  
The GFPuv (cycle 3) variant was specifically used in this study [48]. This 
particular GFP contains three point mutations to amino acids of the protein β-sheet that 
discourage formation of GFP inclusion bodies, increase the hydrophilicity of the 
molecule, and result in 18 to 45 times brighter fluorescence than wild-type GFP [48-49].  
It has been previously reported that fusions onto amino- or carboxy-termini of GFP do 
not inhibit fluorescence, which makes GFP an ideal reporter for studies involving genetic 
fusion [50].  
 A number of models and software analysis tools have been developed to predict 
protein localization, such as TMHMM and SignalP [51-52]. Additionally, factors like 
37 
 
signal peptide hydrophobicity and amino acid charge are known to affect protein export 
[23, 36]. The biological complexities, however, of secretory mechanisms justify a trial-
and-error based approach using multiple signal peptides [2]. The four signal peptides 
selected for analysis were HlyA, TorA, GeneIII, and PelB so as to represent the common 
type I and type II TAT- and Sec-dependent mechanisms [2, 10, 53-54]. The sequences of 
these parts are provided as Table 3.1.  
 
 
Synthetic biological engineering principles were implemented into the design of 
this research due to the number of genetic parts required and the need to maintain 
structural consistency between devices. There are a number of reviews that discuss the 
basic tenets and emphases within the field [60-65]. The specific concepts of 
standardization and abstraction [60-61] were practically applied in this study to 
efficiently construct genetic devices and to utilize “BioBricks” available in the Registry 
of Standard Biological Parts.  A previous study utilized the BioBrick model to construct a 
type III secretion device in Salmonella [66]. 
Table 3.1. Signal peptide sequences 
Signal Peptide  Amino Acid Sequence  Pathway  References 
HlyA  
LAYGSQGDLNPLINEISKIISAAGSFDVKEE
RTAASLLQLSGNASDFSYGRNSITLTTSA  
Type I   [29-30] 
TorA  
MNNNDLFQASRRRFLAQLGGLTVAGMLGP
SLLTPRRATAAQA  
Type II (TAT)  [55-56] 
GeneIII  MKKLLFAIPLVVPFYSHS  Type II (Sec)  [54, 57-58] 
PelB  MKYLLPTAAAGLLLLAAQPAMA  Type II (Sec)  [2, 59] 
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Individual GFPuv and signal peptide parts were designed in accordance with the 
BioFusion standard (BBF RFC 20) because the original BioBrick standard (BBF RFC 10) 
is not conducive to genetic fusion [67]. Despite certain disadvantages, like the presence 
of a rare and positively-charged arginine amino acid in the formed ligation scar, 
BioFusion was selected over recently developed Freiburg (BBF RFC 25) and BglBricks 
(BBF RFC 21) standards because of retained compatibility with original BioBrick parts 
[67-68]. This study demonstrates that the BioFusion and BioBrick standards can be 
implemented to elicit GFP translocation using multiple signal peptides in E. coli.  
 
Materials and Methods 
 
BioBrick Construction, Primers, and Vectors 
 
 Several genetic parts and devices were constructed for analyzing GFP export. 
Table 3.2 presents the oligonucleotides and primers used in this study. GeneIII and PelB 
signal peptides were constructed by annealing forward and reverse oligonucleotides with 
XbaI and SpeI overhanging ends for ligation into vector pSB1AK3 (GeneIIIFORoligo, 
GeneIIIREVoligo, PelBFORoligo, PelBREVoligo). TorA and HlyA signal peptides were 
designed using Gene Designer to include the BioFusion standard prefix and suffix [67], 
synthetically produced (DNA 2.0, Menlo Park, CA), and ligated into pSB1AK3 [69]. The 
GFPuv BioFusion-compatible BioBrick was isolated by PCR with primers 
GFPuvFORprefix and GFPuvREVsuffix. The GFPuv PCR product was isolated by gel 
electrophoresis, purified, subjected to restriction enzyme digestion with EcoRI and PstI, 
and ligated into pSB1AK3. Parts obtained from the Registry of Standard Biological Parts 
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include the lac promoter (BBa_R0010), ribosome binding site (BBa_B0034), and double 
terminator (BBa_B0015) [69].  
 
 
Complete BioBrick devices were constructed through a stepwise series of 
restriction enzyme digestions, ligations and transformations. The basic structure of an N-
terminal signal peptide protein fusion device is depicted in Figure 3.1. All DNA-
modifying enzymes were purchased from Fermentas (Glen Burnie, MD). One Shot® 
Top10 Chemically-Competent E. coli (Invitrogen, Carlsbad, CA) were used for BioBrick 
Table 3.2. Oligonucleotides (prefix/suffix overhangs are bolded, restriction enzyme 
recognition sites are underlined) 
Oligo/Primer  Sequence (5' 3')  Reference 
   
GeneIIIFORoligo ctagaatgaaaaaattattattcgcaattcctttagttgttcctttctattctcactcca This study 
GeneIIIREVoligo 
ctagtggagtgagaatagaaaggaacaactaaaggaattgcgaataataattttttc
att 
This study 
PelBFORoligo 
ctagaatgaaatacctgctgccgaccgctgctgctggtctgctgctcctcgctgccc
agccggcgatggcca 
This study 
PelBREVoligo 
ctagtggccatcgccggctgggcagcgaggagcagcagaccagcagcagcggt
cggcagcaggtatttcatt 
This study 
GFPuvFORprefix gaattcgcggccgcttctagaatggctagcaaaggagaaga This study 
GFPuvREVsuffix ctgcagcggccgctactagtttatttgtagagctcatcca This study 
LacRBSFOR gaattcgcggccgcttctagagcaatacgcaaaccgcctctc This study 
LacRBSREV ctgcagcggccgctactagtatttctcctctttctctagta This study 
HlyAREV ttattatgctgatgtggtca This study 
TorAFOR atgaacaataacgatctctt This study 
GeneIIIFOR atgaaaaaattattattcgc This study 
PelBFOR atgaaatacctgctgccgac This study 
GFPuvFOR atggctagcaaaggagaaga This study 
GFPuvREV ttatttgtagagctcatcca This study 
VF2 (BBa_G00100) tgccacctgacgtctaagaa [69] 
VR (BBa_G00101) attaccgcctttgagtgagc [69] 
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transformations. Proper construction was confirmed for all parts and composite devices 
by sequencing analysis with primers VF2 and VR [69] using an ABI prism 3730 DNA 
Analyzer and Taq FS Terminator Chemistry. Transformation colony selection was 
carried out using LB agar plates containing appropriate antibiotics. 
 
 
 
 
Figure 3.1 Composite structure of an N-terminal signal peptide protein fusion device. 
 
 
Strains and Growth Conditions 
 
E. coli BL21-Gold (DE3) (Stratagene, La Jolla, CA), lacking Lon and OmpT 
proteases, was used for expression and secretion studies with the various signal peptide-
GFPuv devices. E. coli were precultured from glycerol freezer stocks in 5 ml LB medium 
supplemented with 50 µg/ml of ampicillin and 25 µg/ml of chloramphenicol to an OD600 
of about 1.5. Precultures were used to inoculate 150 ml of LB (1:100 v/v dilution) 
containing appropriate antibiotics. IPTG was added after 1 hr of growth to a final 
concentration of 0.1 mM [70]. Cultures were grown for a total of 3-4 hours to an OD600 of 
about 1.0, divided into two 50 ml aliquots, and harvested by centrifugation at 4000 x g 
for 20 minutes. Approximately 100 ml of supernatant were concentrated to 0.5 ml using 
Centricon® YM-10 centrifugal filter devices (Millipore, Bellerica, MA) and analyzed for 
GFP secretion to the extracellular media. 
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Cellular Fractionation 
 
Harvested cells were washed with 10 mM Tris (pH 8.0). Spheroplast formation 
was carried out by either lysozyme/EDTA/osmotic shock [71-73] or by chloroform 
treatment [74]. Each method was carried out on 50 ml of cell culture. The general 
principles of fractionation by lysozyme/EDTA/osmotic shock have been previously 
discussed [71-73]. The cell pellet was resuspended in 0.5 ml of buffer (20% sucrose, 1 
mM EDTA, 50 µg/ml lysozyme), incubated on ice for 5 minutes, and subjected to 
osmotic shock by addition of 0.5 ml of cold ddH2O for 5 minutes. For the chloroform 
method [74], the washed cell pellet was resuspended in 250 µl of 10 mM Tris-HCl (pH 
8.0) and approximately 10 µg of cold chloroform was added gradually while swirling the 
solution. After incubation at room temperature for 15 minutes, another 750 µl of 10 mM 
Tris-HCl was added.  
The periplasmic fractions were recovered by separation of spheroplasts by 
centrifugation at 12,000 x g for 10 minutes. The cell pellets were resuspended in 500 µl 
of 10 mM Tris-HCl buffer and sonicated for 15 seconds on ice, centrifuged to separate 
unlysed cells, and subjected to an additional sonication. The cytoplasmic and membrane 
fractions were separated by ultracentrifugation at 103,000 x g for 1.25 hours. The o-
nitrophenyl-β-galactopyranoside assay [75] was used to determine β-galactosidase 
activity, and a basic ρ-nitrophenylphosphate hydrolysis procedure was used to determine 
alkaline phosphatase levels [76]. For both colorimetric assays, A410 was measured.  Total 
protein concentrations were determined using the Modified Lowry Assay Kit (Thermo 
Scientific Pierce, Rockford, IL). 
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SDS-PAGE and Western Blotting 
 
Protein samples were mixed with sample loading buffer, heated for 1 min, and 
analyzed by SDS-PAGE using 12% polyacrylamide tris-glycine gels (Jule Inc., Milford, 
CT). Gels were run in accordance with manufacturer guidelines. Approximately 40 μg of 
total protein was loaded for the cytoplasmic, periplasmic, and membrane fractions. An 
equal volume of concentrated supernatant was used for each of the various signal 
peptide-GFP constructs. Coomassie Brilliant Blue stain was used to visualize protein 
bands on the gels. For Western blot analysis, gel proteins were transferred to PVDF 
membrane and blocked for 3 hours in 5% nonfat dry milk TBST (10 mM Tris, 150 mM 
NaCl, pH 8.0, and 0.1% Tween 20).  GFPuv Polyclonal (Cat No.: AF4240) and Anti-
Goat IgG HRP conjugated (Cat No.: HAF017) antibodies were purchased from R&D 
Systems (Minneapolis, MN). Membranes were incubated overnight at 4ºC with GFPuv 
primary antibody (1:2000 v/v dilution, 0.1 µg/ml final antibody concentration) in 0.5% 
nonfat dry milk TBST.  An incubation time of 1 hour was used for the anti-goat 
secondary antibody (1:1000 v/v dilution), followed by the addition of TMB stabilized 
substrate (Promega, Madison, WI) for protein detection.  A Kodak® Image Station 2000 
(Rochester, NY) and Kodak® 1-D Image Analysis Software were used to determine 
relative and net intensities for gels and immunoblots. 
 
Fluorometry and Fluorescence Microscopy 
 
A Synergy™ 4 Multi-Mode Microplate Reader with Hybrid Technology™ 
(BioTek, Winooski, Vermont) was used for measuring GFP fluorescence at respective 
excitation and emission wavelengths of 480 nm and 510 nm [37, 70]. An inverted 
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microscope (Nikon Eclipse Ti-U, Melville, NY) equipped with a B-2A Longpass 
Emission filter set, a Photometrics® CoolSNAP HQ
2 
high-resolution camera, and a 100 
X oil immersion objective was used. BL21-Gold (DE3) cells harboring various GFP 
constructs were harvested at an OD600 of about 1.0 and mounted on Fisherbrand® 
precleaned plain microscope slides. NIS-Elements AR software was used for capturing 
fluorescence microscopy images. 
 
Results 
 
Construction of GFP BioFusion Devices 
 
To facilitate more rapid assembly, a single lac promoter/ribosome binding site 
part was constructed by PCR of part BBa_K084007 with primer LacRBSFOR and 
LacRBSREV, which is now available in the BioBrick Registry as BBa_K208010 (see 
Appendix A, Table A.3). Although it is advised to remove the start codon from 
BioFusion parts to prevent errant translation and formation of unfused proteins [67], the 
ATG of the GFPuv sequence was retained so that this coding region could be directly 
used for C-terminal fusion with the HlyA signal peptide. 
Composite GFP devices were digested with EcoRI and PstI and ligated into 
pSB1A3 (pMB1 origin of replication, ampicillin resistance). These plasmids were then 
cotransformed into BL21-Gold (DE3) with plasmid pLG575 (p15A origin of replication, 
chloramphenicol resistance) harboring tet-regulated HlyBD proteins [77].  Although the 
HlyB and HlyD proteins are only necessary for functionality of the HlyA signal peptide, 
all constructs were cotransformed with pLG575 to maintain consistency and allow for 
comparison across the different signal peptide systems. Confirmation of proper 
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transformation was carried out using antibiotic selection and PCR with various signal 
peptide and GFPuv specific primers. 
A list of complete BioBrick devices constructed for this study is given as Table 
3.3. In addition to these functional devices, several intermediate composite parts were 
also produced (see Appendix A, Table A.5). The basic functionality of several parts was 
confirmed using visual and measurable detection of GFP fluorescence by an ultraviolet 
transilluminator, a fluorometric analysis, and fluorescence microscopy. Two negative 
controls were also constructed as shown in Table 3. The GFP (-) device contained only a 
signal peptide, and a pSB1A3 construct was made by digestion with XbaI and SpeI and 
ligation of compatible ends to remove the coding region. 
 
 
Analysis of GFP Translocation 
 
To ensure proper subcellular fractionation, two methods were carried out on cell 
samples and evaluated because the host organism and its physiological state can affect 
the efficacy of fractionation procedures [73].  In both procedures, aggregation of the cells 
indicated spheroplast formation.  
Table 3.3. Description of final BioBrick composite parts 
Designation Description 
  
GFPuv Lac promoter, GFPuv BioFusion BioBrick without signal peptide, pSB1A3 
GFPuv:HlyA GFPuv C-terminal fusion with HlyA signal peptide, Lac promoter, pSB1A3 
TorA:GFPuv GFPuv N-terminal fusion with TorA signal peptide, Lac promoter, pSB1A3 
GeneIII:GFPuv GFPuv N-terminal fusion with GeneIII signal peptide, Lac promoter, pSB1A3 
PelB:GFPuv GFPuv N-terminal fusion with PelB signal peptide, Lac promoter, pSB1A3 
GFP (-) A GFP negative strain expressing only a signal peptide, Lac promoter, pSB1A3 
pSB1A3 pSB1A3 plasmid without insert coding region 
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Colorimetric assays for alkaline phosphatase and β-galactosidase were used to 
evaluate both lysozyme/EDTA/osmotic shock and chloroform subcellular fractionation 
procedures. For the biological systems used in this study, it was determined that the 
chloroform method more consistently led to successful fractionation of cellular 
compartments as demonstrated by measured activity of periplasmic alkaline phosphatase 
and cytoplasmic β-galactosidase. For both methods, the activity of β-galactosidase in the 
cytoplasmic fraction was consistently 80-90% of the total measured activity in all 
fractioned samples. This confirms minimal premature lysis of the inner membrane. 
Proper determination of β-galactosidase is particularly important to ensure minimal 
cellular lysing and leakage of cytoplasmic components. Alkaline phosphatase activity 
measurements were highest in periplasmic fractions for samples fractioned by the 
chloroform method, and represented as much as 65-75% of the total measured activity in 
all fractions. Successful periplasmic fractionation was less consistent using the 
lysozyme/EDTA/osmotic shock method and measured alkaline phosphatase activity 
ranged from 25.9% to 67.9% of the total enzyme activity from all samples.  
 Samples retrieved by the chloroform fractionation protocol were analyzed by 
SDS-PAGE and immunoblotted with GFPuv-specific antibodies. Equivalent amounts of 
total protein were loaded for cytoplasm, periplasm, and membrane fractions. 
Densitometric analysis was used to determine differences in band intensities. 
Polyacrylamide gels and corresponding Western blots are given as Figure 3.2 for each of 
the four signal peptide constructs. 
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Figure 3.2 Immunoblotting and corresponding SDS polyacrylamide gels of subcellular 
fractions for (A) GFPuv:HlyA, (B) TorA:GFPuv, (C) GeneIII:GFPuv, and (D) 
PelB:GFPuv. C – cytoplasmic fraction, P – periplasmic fraction, M – membrane fraction, 
S – concentrated supernatant (media) fraction. The position of GFPuv bands varies from 
roughly 27-30 kDa, and this size discrepancy between bands is a result of fusion with 
signal peptides.  
 
 
Targeting GFP using the HlyA signal peptide (Fig. 3.2A) led to detection of the 
protein in concentrated supernatant samples, whereas lesser amounts of GFP were found 
in the extracellular media for the other three signal peptides. Densitometric analysis of 
supernatant band intensities verified the relative amount of GFP detected in HlyA 
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supernatant samples to be roughly 10 times larger than the TorA:GFPuv and 
GeneIII:GFPuv supernatant bands. No GFP was detected in the supernatant fraction of 
PelB:GFPuv. Significant levels of GFPuv were also detected in the periplasmic and 
membrane fractions of GFPuv:HlyA samples. This is a unique observation, and is 
presumably a result of incomplete translocation of targeted GFPuv due to the structure of 
the genetic device.  
Three bands are present in TorA:GFPuv fractions (Fig. 3.2B), which is consistent 
with previously published Western blotting results for TorA/GFP fusions [39, 41]. The 27 
kDa band is likely unfused GFPuv, the middle form (~28 kDa) is possibly a degraded 
form of fused GFPuv [40-41], and the largest band (~29 kDa) is likely GFPuv fused with 
TorA. The most prevalent GFPuv form in the periplasm was the unfused 27 kDa form. 
The relative intensity of the 27 kDa periplasmic band was determined as 58%, and the 
relative intensity of the middle band (28 kDa) represented 28% of the total intensity of 
the three bands in the sample.  This indicates significant GFP translocation to the 
periplasmic space and cleavage of the TorA signal peptide. In membrane fractions, the 
largest form (about 29 kDa) was most prevalent. This verifies that some of the TorA-
GFPuv fusion protein is unable to cross the inner membrane, either due to overwhelming 
the membrane components of the TAT secretory machinery [39] or the positive charge 
near the N-terminal of the recombinant protein [78].  
Like the TorA samples, the majority of GFP in the periplasmic fractions from 
GeneIII:GFPuv samples was represented as the 27 kDa form without signal peptide (Fig. 
3.2C). However, the predominance of this band was not as significant as the cleaved 
GFPuv in TorA directed translocation. The GFP in the membrane fraction for the GeneIII 
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construct was almost entirely fused to the GeneIII signal peptide, again indicating GFP 
entrapment in the inner membrane.  
The PelB signal peptide system did not effectively target GFP for translocation 
across the inner membrane (Fig. 3.2D). Several repeated analyses of samples led to the 
conclusion that the PelB:GFPuv BioFusion construct primarily led to GFP entrapment in 
the membrane. The cytoplasmic levels of GFPuv were comparatively low, and the 
predominant location of GFPuv was in membrane samples.  
 
Fluorescence Analysis 
 
 The effect of signal peptide fusion on GFP fluorescence was examined. In 
addition to observed differences in translocation response between signal peptides, the 
fluorescence output varied substantially as a result of the signal peptide fusion. As shown 
by cells expressing the recombinant proteins (Fig. 3.3A), the visual differences in 
fluorescence activity are significant. Although both the HlyA- and TorA-GFP fusion 
proteins were strongly fluorescent, their activity was lower than that of unfused GFP. The 
exact cause of this observation is unknown, but it has been demonstrated that GFP fusion 
with TorA can lead to elevated protein degradation [40]. Additionally, the fusion of 
signal peptides could adversely affect GFP folding. Furthermore, there is some evidence 
that membrane-bound GFP has diminished fluorescence activity [39], which may affect 
total fluorescent output.  
It is reported that fusion of GFP to type II Sec-dependent signal peptides 
diminishes GFP fluorescence [79]. This same phenomenon was detected for Sec-
dependent signal peptides used in this study. The PelB-GFP fusion protein was found to 
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be completely inactive (Fig. 3.3A and 3.3B). Fluorescence measurement values were 
nearly identical to those obtained for GFP (-) and pSB1A3 (no coding region) samples 
(Fig. 3.3B). GFP fused with Sec-dependent GeneIII signal peptide emitted detectable 
fluorescence, although the measurable activity was significantly lower than other 
fluorescent proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Difference in BL21-Gold (DE3) GFPuv fluorescence activity as a result of 
signal peptide fusions. (A) Observational difference in fluorescence activity for cells 
grown on LB-ampicillin plates. (B) Whole cell relative fluorescence. 
 
 
Fluorescence microscopy analysis was performed for all GFP constructs emitting 
significant fluorescence. In Fig. 3.4A, GFP is shown evenly distributed throughout cells 
expressing the unfused protein. In contrast, further evidence of GFP translocation by the 
TorA signal peptide was demonstrated by a “halo” appearance of accumulated active 
GFP in the periplasm of the cells (Fig. 3.4B). All examined cells harboring TorA:GFPuv 
clearly exhibited this effect. This demonstrates that BioBrick technical standards can be 
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used to make a functional TorA signal peptide construct for translocation of active, 
folded proteins. The results of fluorescent microscopy analysis are consistent with those 
observed on immunoblots. Microscopic analysis of HlyA- and GeneIII-GFP fusions 
demonstrate a translocation effect as dramatic as that observed with TorA, although some 
GeneIII-GFP fusion-expressing cells appear to show a slight degree of possible 
periplasmic accumulation (Figs. 3.4C and 3.4D). PelB:GFPuv samples were not 
significantly fluorescent and imaging could not be carried out.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Fluorescence microscopy imaging for (A) GFPuv (B) TorA:GFPuv (C) 
GFPuv:HlyA and (D) GeneIII:GFPuv. All of the above images were obtained using a 100 
X objective lens. 
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The fluorescence intensity was measured in concentrated media samples for each 
of the signal peptide/GFP devices. Fluorescence was also measured in pSB1A3 (no 
coding region) supernatant samples and subtracted from each replicate to obtain final 
fluorescence values.  The averages and standard deviations were calculated (Fig. 3.5). 
Detected fluorescence in the GFPuv:HlyA supernatant samples was significantly higher 
than that measured for other signal peptide devices, thereby further demonstrating the 
presence of a significant amount of HlyA-targeted GFP in the extracellular medium. 
Targeting GFP with TorA, GeneIII, and PelB signal peptides did not result in measured 
fluorescence significantly elevated above the pSB1A3 negative control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Measurement of fluorescence in concentrated extracellular media. 
 
 
Discussion 
 
 This study demonstrates that the BioBrick and BioFusion technical standards can 
be used to construct devices for type I and type II secretory translocation of GFP in E. 
coli. Transforming E. coli with pLG575 expressing HlyB and HlyD proteins and 
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targeting GFP by fusion with HlyA signal peptide led to elevated levels of GFP in the 
extracellular media, as detected by immunoblotting and fluorometry. To our knowledge, 
recombinant GFP secretion using the HlyA signal peptide has not been previously 
reported for E. coli. TorA signal peptide effectively targeted GFP to the periplasmic 
space. Strong GFP-associated bands were detected by immunoblotting with periplasmic 
fractions and accumulation of active GFP in the periplasm was visibly apparent by 
fluorescence microscopy. Unlike previous studies, the TorA:GFPuv device used in this 
study was made entirely using BioBrick and BioFusion technical standards. Targeting 
with Sec pathway signal peptides was not as clearly successful in eliciting GFP export. 
GeneIII fusions indicated GFP localization to the periplasm. However, the PelB:GFPuv 
construct was found to be ineffective with the majority of GFP localized to the inner 
membrane. This inability of PelB to induce GFP translocation demonstrates that an 
attached signal peptide does not in itself guarantee export of a protein [23] and factors 
surrounding the genetic design require consideration.  
One of the frequently discussed disadvantages with the BioFusion model is the 
presence of the rare arginine codon AGA in the ligation scar [67-68]. The concerns 
surrounding the presence of arginine are a result of its charge and prevalence in E. coli. 
Due to its positive charge, arginine has potential to adversely affect protein translocation. 
Specifically, a net positive charge within the first five amino acids near the C-domain 
cleavage site of the signal peptide can inhibit proteins from entering the lipid bilayer and 
reduce protein export efficiency by as much as 50-fold [78].  In this study, significant 
GFP was observed in the membrane fractions for all signal peptides, and this issue was 
particularly problematic when using the PelB signal peptide. One method to circumvent 
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this issue and potentially increase export efficiency is to use single-point mutation after 
construction of the device to remove the arginine amino acid and replace it with a neutral 
molecule. Removing the arginine would also counter any negative effects related to 
expression errors associated with the rarity of the AGA codon in E. coli [80-81].   
 Another concern with the BioFusion standard is related to the suggestion to 
remove the start codon for the second of the two compatible parts [67], as this would 
require N-terminal fusion or ligation with a separate start codon BioBrick. The GFP 
fusion-compatible BioBrick in this study retained its start codon to allow for this same 
part to be used in all devices.  The GFPuv:HlyA construct devised for this study has only 
one start codon, located at the N-terminus of the GFP coding region. The rest of the 
fusion devices, however, had an additional start codon. Unfused GFP forms were 
significant in the cytoplasmic fractions, perhaps as a result of aberrant translation of the 
second start codon [67] or from proteolysis [39-41]. This discussed issue, however, did 
not prohibit translocation of GFP. The design used in this study resulted in functional 
secretory devices. 
 The fluorescence intensity of GFP was measurably affected by fusion with signal 
peptides, despite reports that indicate that genetic fusion does not have an effect on GFP 
activity. Based on previous reports, it was expected that Sec-dependent signal peptides 
would diminish GFP activity [79], which was observed. However, fluorescence was also 
diminished considerably after GFP fusion with HlyA and TorA signal peptides. From 
fluorometric analysis, it was demonstrated that whole cell samples producing unfused 
GFP fluoresced 8 times more intensely than the GFPuv:HlyA samples. It has been 
demonstrated that the TAT-dependent TorA signal peptide is useful for translocation of 
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fully-folded and active GFP, however, these studies did not necessarily compare the 
whole cell fluorescence of TorA constructs with untargeted GFP following a similar 
construction format. Like the signal peptide devices, the untargeted GFP construct was 
carried in the pSB1A3 plasmid and cotransformed with pLG575 into BL21-Gold (DE3). 
The size of the protein coding region, the BioFusion scar, and interactions with secretion 
machinery may play a role in the diminished fluorescence activity. It was also noted that 
the GeneIII signal peptide emitted slightly higher fluorescence activity than the other 
Sec-dependent signal peptide, PelB.  
 
Conclusions 
 
The use of BioBrick and BioFusion technical standards allowed for efficient 
design and assembly of multiple biological composite parts that followed a consistent 
format. The functionality of the constructed parts was demonstrated, as evidenced by 
significant levels of detectable GFP in the extracellular medium and the intracellular 
periplasm. The utility of biological standards for genetic device construction is reinforced 
in this study by demonstrating the advantages of using a standardized format. For 
example, basic parts (lac promoter, ribosome binding site, and double terminator) created 
by other research groups were obtained from a repository and used in assembled 
composite parts that successfully resulted in GFP translocation to the extracellular 
medium or periplasmic space. Additionally, the specific individual signal peptide-GFP 
fusion BioBricks created for this investigation can now be implemented directly by other 
researchers studying type I and II protein secretion. This allows for the user to design 
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genetic systems in a controlled manner and to eliminate much of the repeated work of ad 
hoc design and construction of specific components.  
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 CHAPTER 4  
 
COMPARISON OF SINGLE-STEP EXTRACTION FOR 
1
H NMR ANALYSIS  
WITH GC AND FLUORESCENCE TECHNIQUES FOR 
POLYHYDROXYALKANOATE QUANTIFICATION
2 
 
Abstract 
 
In this study, an 
1
H NMR-based method was developed to quantitatively analyze 
the PHA content in Cupriavidus necator H16, Azotobacter vinelandii AvOP, and mixed 
microbial cultures from the effluent of an agricultural waste treatment anaerobic digester. 
In contrast to previous methods, we performed a single-step PHA extraction using 
deuterated chloroform, which leaves the PHA in a solvent suitable for direct 
1
H NMR 
analysis. We verified the accuracy of our method by comparison with the well-
established GC methanolysis technique. Nile blue fluorescence staining was also carried 
out to serve as an independent and qualitative indicator of intracellular PHA content. Our 
results show that 
1
H NMR correlates closely with traditional methods for detecting 
PHAs. The 
1
H NMR method is appropriate for rapid and non-destructive quantification 
of overall PHA content as well as for determination of PHA copolymer composition. 
Notably, this technique was effective in measuring PHA content in full-strength waste 
samples where high concentrations of background impurities and organic compounds are 
present. The straightforward procedures used for extraction of intracellular PHA 
minimized error-introducing steps, required less time and materials, and resulted in a 
simple and overall accurate method suitable for routine analyses. 
  
 
2  
Coauthored by Elisabeth Linton, Sridhar Viamajala, and Ronald C. Sims. 
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1. Introduction  
Polyhydroxyalkanoates (PHAs) are a diverse class of polyesters that represent a 
source of non-petrochemically-derived biodegradable plastics (Anderson and Dawes, 
1990; Brandl et al., 1990; Byrom, 1987; Doi, 1990; Lee, 1996). A variety of 
microorganisms accumulate PHAs when excess carbon substrate is available and cellular 
growth is limited due to an environmental stress or nutrient limitation (Doi, 1990; Lee, 
1996; Madison and Huisman, 1999; Verlinden et al., 2007). Polyhydroxybutyrate (PHB) 
represents a prevalent and commonly studied type of PHA that has material properties 
comparable with polypropylene (Byrom, 1987; Holmes, 1985; Steinbüchel and 
Füchtenbusch, 1998). Variations in PHA composition are a function of the organism, 
metabolic pathway, and available precursor substrates (Anderson and Dawes, 1990; 
Madison and Huisman, 1999; Reddy et al., 2003; Steinbüchel and Füchtenbusch, 1998).  
For example, the availability of volatile fatty acids like valerate and propionate lead to 
the formation of PHB and polyhydroxyvalerate (PHV) copolymers, P(HB-co-HV) (Doi, 
1990; Du et al., 2001; Oehmen et al., 2005a; Satoh et al., 1994; Serafim et al., 2008; 
Shang et al., 2004). An increased proportion of HV units in the copolymeric structure 
corresponds with enhanced polymer elasticity and impact strength, as well as decreased 
processing temperatures (Luzier, 1992; Madison and Huisman, 1999). Therefore, the 
material properties of PHAs can potentially be tailored for specified applications by 
adjusting the copolymeric composition (Braunegg et al., 1998; Luzier, 1992).   
The efforts to improve PHA production and characterization methods are largely 
due to the potential of these bioplastics to serve as a renewable and sustainable substitute 
for fossil-derived polymers (Byrom, 1987; Holmes, 1985; Steinbüchel and Füchtenbusch, 
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1998). Additionally, high PHA compatibility with human systems has led to use in 
medical applications, such as orthopedic materials and sutures (Chen and Wu, 2005; 
Holmes, 1985; Steinbüchel and Füchtenbusch, 1998; Volova et al., 2003; Williams and 
Martin, 2002). High costs, however, have limited widespread application of the bioplastic 
(Byrom, 1987; Castilho et al., 2009; Choi and Lee, 1997; Lee, 1996; van Wegen et al., 
1998). Reported economic analyses based on various current industrial practices have 
placed the cost of PHAs between $2.65-5/kg (Akiyama et al., 2003; Castilho et al., 2009; 
Choi and Lee, 1999; Choi and Lee, 1997). In contrast, the average cost of 
petrochemically-derived plastic is around $1.57-1.67/kg for high-density polyethylene 
and $2.11-2.16/kg for polypropylene (Plastics News, 2009).   
Although petrochemical plastics are currently less expensive than PHAs, a 
number of studies suggest that alternative production methods utilizing low value waste 
feedstocks and mixed microbial cultures may decrease PHA production costs and energy 
requirements (Bengtsson et al., 2008; Khardenavis et al., 2007; Park et al., 2002; Serafim 
et al., 2008). More specifically, one intriguing approach integrates PHA production with 
waste treatment systems.  In this process, polyphosphate accumulating organisms (PAOs) 
are enriched to simultaneously achieve biological phosphorus removal and bioplastic 
production (Comeau et al., 1986; Mino et al., 1998; Seviour et al., 2003).  In these 
complex environmental systems, as well as in traditional fermentative processes that 
employ pure cultures, efficient quantification and chemical characterization of PHA is 
critical for process development, monitoring, and optimization.   
A number of methods have been developed for the estimation of PHA content, 
including fluorometry, gravimetry, and spectrophotometry (Furrer et al., 2007; Serafim et 
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al., 2002).  Of these, Nile blue A sulfate staining is perhaps the most rapid method, which 
is based on fluorescent detection of dye bound to intracellular PHA (Kitamura and Doi, 
1994; Ostle and Holt, 1982; Page and Tenove, 1996; Spiekermann et al., 1999). 
However, Nile blue non-selectively binds to non-PHA materials like waxes and lipids 
and can result in inaccurate and inconsistent measurements (Spiekermann et al., 1999).  
Gravimetric and spectrophotometric methods are time intensive and require substantial 
amounts of PHA-containing sample and/or several replicate measurements to ensure an 
acceptable level of accuracy (Serafim et al., 2002). Like the fluorescence staining 
method, gravimetric and spectrophotometric methods are also susceptible to interference 
by cell materials and lipids (Braunegg et al., 1978; Serafim et al., 2002). Furthermore, 
none of the discussed methods provide information on PHA composition, and are 
therefore insufficient for microbial systems that are likely to produce mixtures of PHA 
polymers. 
Gas chromatography methods determine the actual chemical components of PHA, 
thereby providing a measurement of both PHA content and composition (Braunegg et al., 
1978; Comeau et al., 1988). Accordingly, GC is one of the most commonly used methods 
for PHA analysis (Oehmen et al., 2005b). Preparation of samples for GC analysis 
requires extraction, depolymerization, and derivatization of the PHA to produce alkyl 
esters (Braunegg et al., 1978). Commonly, a single-step reactive extraction with a 
mixture of acidified alcohol and solvent is carried out on PHA-containing samples to 
generate transesterified monomers of 3-hydroxyalkanoates (Braunegg et al., 1978; 
Oehmen et al., 2005b). Methanolysis and propanolysis derivatization methods are used 
for quantifying PHAs by GC (Baetens et al., 2002) but incomplete depolymerization or 
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transesterification during the reactive extraction step can lead to inaccuracies in 
measurements (Doi, 1990; Serafim et al., 2002). The loss of sample integrity during the 
derivatization steps also renders PHA unsuitable for other characterization, such as by 
spectroscopy or calorimetry. Furthermore, peak overlap can cause uncertainty in 
quantification (Serafim et al., 2002), particularly in samples containing mixed alkanoate 
polymers or when evaluating environmental samples with high organic loads (e.g. 
samples from activated sludge). Finally, the presence of cellular debris and acid can lead 
to mechanical issues and deterioration of the GC column (Serafim et al., 2002).  
Nuclear magnetic resonance (NMR e.g. 
1
H NMR and 
13
C NMR) spectroscopy is a 
diagnostic tool that is routinely used for PHA structural analysis and metabolic pathway 
studies (de Rijk et al., 1998; Doi et al., 1989; Lemos et al., 2003) but has received less 
attention for routine quantification of PHA polymers, particularly in environmental 
samples. Like GC, the peak area of an NMR signal is linearly proportional to the 
concentration of the analyte. The unique splitting patterns of signals in the NMR 
spectrum enable structural determination of the compound that could otherwise require 
mass spectrometric analysis if GC-based methods had been used (de Rijk et al., 1998). 
Further, unlike GC methods that require polymer breakdown and transformation, NMR 
can be performed on whole PHA extracts, thereby leaving the polymer intact for other 
analyses (Doi, 1990). Short analysis time (5-7 minutes) is another advantage of 
1
H NMR.   
Previous studies using NMR for PHA characterization have generally employed 
extensive and time-consuming purification methods that do not necessarily improve the 
ease or accuracy of quantification (Dai et al., 2008; Furrer et al., 2007; Ivanova et al., 
2009; Jan et al., 1996; Shang et al., 2004). For example, Jan et al. (1996) performed 
67 
 
preliminary extraction of PHB from cells using sodium-hypochlorite/chloroform 
dispersion, followed by polymer purification procedures. Eventually, pure PHA extract 
was dissolved in deuterated chloroform (CDCl3)for 
1
H NMR analysis (Jan et al., 1996). 
This multi-step sample preparation by extraction, purification, and dissolution of the 
polymer increases potential inaccuracies due to material loss, and significantly extends 
preparation time and solvent requirements. As another example, Ivanova et al. (2009) 
used a 20 h PHA extraction procedure with chloroform, followed by redissolution of the 
polymer in CDCl3. Similar time-consuming methods were also employed by Dai et al. 
(2008) and Shang et al. (2004). Due to a lack of direct and efficient sample preparation 
techniques, routine use of 
1
H NMR for PHA quantification has been limited (Furrer et al., 
2007).  
Quantitative 
1
H NMR-based measurement has primarily been applied to pure 
PHB (Jan et al., 1996), although Dai et al. (2008) recently used 
1
H NMR to measure PHA 
copolymers in environmental samples. In that study, however, the PHAs were measured 
in samples taken from a sequencing batch reactor that had been seeded with domestic 
wastewater sludge (Dai et al., 2008) instead of measuring the PHA content in full-
strength waste samples, which have higher organic load and levels of impurities. In 
contrast, the objectives of our study were to evaluate the accuracy of the 
1
H NMR-based 
method in comparison to traditional GC and fluorescence staining methods in a variety of 
PHA-containing samples, and to evaluate whether the complex composition of full-
strength agricultural waste samples interferes with 
1
H NMR measurements. An improved 
extraction procedure that leaves the PHA in a solvent suitable for direct 
1
H NMR analysis 
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would allow for efficient and reliable measurement of PHA content, and was the overall 
aim of this investigation. 
 
2. Materials and Methods 
2.1. Chemicals 
Standard PHB (Product No. 363502) and P(HB-co-HV) (12% HV) (Product No. 
403121) were obtained from Sigma-Aldrich Co. (St. Louis, MO). Sulfuric acid (95-98% 
c. p.) and deuterated chloroform (99.8% atom-D) with 0.03% (v/v) tetramethylsilane 
(TMS) were purchased from Acros Organics (Thermo Fisher Scientific, Morris Plains, 
NJ). All other chemicals, solvents, and reagents were purchased from Fisher Scientific 
Research (Pittsburgh, PA) and were of analytical grade. 
 
2.2. Experimental Design 
To validate the 
1
H NMR-based method for PHA quantification, 
1
H NMR 
calibration curves were first constructed using gravimetrically measured PHB and P(HB-
co-HV) standards (0-12 mg/mL) to correlate NMR peak areas with PHA concentration.  
PHA content was determined for two pure bacterial cultures and enriched anaerobic 
digester samples using 
1
H NMR and developed calibration curves. To establish 
applicability of our method over a broad concentration range, samples were periodically 
withdrawn and analyzed during growth. To validate the 
1
H NMR results, PHA content of 
the same samples used for 
1
H NMR analysis were also evaluated using GC/FID 
methanolysis procedures and Nile blue fluorescence staining. Standard curves were 
established for the GC procedure using gravimetrically measured PHB and P(HB-co-HV) 
standards (similar to preparation for NMR calibration) followed by methanolysis. Nile 
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blue fluorescence staining was used as a qualitative method for measuring PHA content 
in order to correlate general trends observed with the two quantitative methods. All 
experiments and analyses were replicated. Growth experiments were carried out in 
duplicate. Standard curves were constructed using triplicate, independently prepared 
standards. A minimum of three replications were used for fluorescence staining 
measurements. 
 
2.3. Microorganisms and Culture  
Methods for Pure Strains 
 
Two PHA-producing microbial strains were used: Cupriavidus necator H16 
(ATCC 17699)(previously Ralstonia eutropha H16) and Azotobacter vinelandii AvOP 
(ATCC BAA-1303), which is a nitrogen-fixing bacterium. A phosphate-limited base 
medium developed by Ryu et al. (1997) with 10 g/L fructose was used for C. necator 
cultivation. This organism accumulates PHA solely in the form of PHB under nutrient-
limitation and in the presence of fructose as the sole carbon source (Kelley and Srienc, 
1999). Burk’s nitrogen-free medium containing 20 g/L sucrose was used for A. vinelandii 
growth (Wilson and Knight, 1952).  
Cells from frozen glycerol stocks (20% v/v) were precultured in 50 mL of 
corresponding media, and late log-phase cultures were used to inoculate (1:70 dilution) 3 
L Kontes® Cytostir® (Kimble Chase Life Science and Research Products, Vineland, NJ) 
stirred bioreactors containing sterile media. Oxygen was supplied by sparging filtered 
(0.22 µm) air into the media. Each strain was grown in duplicate vessels. Approximately 
50 mL of sample were withdrawn periodically during growth to measure culture density 
and PHA content using the methods described in more detail below.   
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2.4. Environmental Samples 
Effluent samples from a pilot-scale anaerobic digester (Wade Dairy, Ogden, UT) 
were used as an environmental source of PHAs. Details of reactor operating conditions 
and parameters are reported elsewhere (Hansen and Hansen, 2002). Digester samples 
were subjected to periodic cycling between aerobic and anaerobic conditions with the 
intent of creating an enriched population of phosphorus accumulating organisms (PAOs) 
(Blackall et al., 2002). PAOs are associated with excessive phosphorus uptake and PHA 
accumulation (Blackall et al., 2002). Consequently, these organisms are employed in 
Enhanced Biological Phosphorus Removal (EBPR) municipal wastewater treatment 
processes (Blackall et al., 2002; Brdjanovic et al., 1998; Mino et al., 1998; Satoh et al., 
1994). PAO enrichment experiments were carried out in 3 L stirred tank reactors, similar 
to those used for growing pure strains as described in the previous section.  A variety of 
volatile fatty acids were present in the waste samples, including acetate (4474.56 mg/L), 
propionate (3196.63 mg/L), iso-butyrate (547.09 mg/L), butyrate (270.35 mg/L), iso-
valerate (879.13 mg/L), and valerate (258.19 mg/L). The PHA concentration and 
composition in anaerobic phase cultures (where PHA content is presumably highest) 
were determined using 
1
H NMR and GC after 3 weeks of cycling when enriched, stable 
populations of PHA-accumulating organisms were expected.  
 
2.5. Sample Preparation  
Pure culture samples were centrifuged at 2000 g and lyophilized in a Labconco 
Lyph-Lock 4.5 freeze-drying unit (Model 77510, Labconco Corporation, Kansas City, 
MO) at -40˚C and 33  10-3 mBar for a minimum of 15 h.  Dry cell weight (DCW) was 
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determined by using the lyophilized biomass - the DCW data was used to construct 
growth curves. Sample preparation for both NMR and GC/FID (extraction and/or 
derivatization) was carried out in 2 mL crimp-top autosampler vials (Fisher Scientific, 
Hanover Park, IL) using 15 (±0.2) mg dry cells. The vials were sealed with PTFE lined 
septa (Fisher Scientific, Hanover Park, IL).  
1
H NMR sample preparation procedures were developed using similar principles 
of a chloroform-sodium hypochlorite dispersion method for PHA extraction (Hahn et al. 
1994), with general modifications and CDCl3 substituted for CHCl3. Approximately 0.7 
mL of a 5% (vol/vol) sodium hypochlorite solution and 1 mL of CDCl3 (0.03% TMS) 
were added to each sample of dried cells. The addition of chloroform substantially 
reduces polymer degradation because the chloroform dissolves the PHAs and minimizes 
its interaction with sodium hypochlorite (Hahn et al., 1994; Jacquel et al., 2008). These 
slurries were vortexed for 10 minutes, followed by incubation on a shaker table for 2 h at 
30˚C. PHA standards were incubated at a higher temperature (50˚C) to facilitate 
dissolution. After the 2 h extraction period, all samples were centrifuged at 1500 g for 
10 min to induce phase separation. The bacterial and environmental samples yielded 
three distinct immiscible phases: (1) a bottom organic layer of CDCl3 and extracted PHA, 
(2) a middle layer of cellular debris, and (3) an upper aqueous layer of sodium 
hypochlorite. The samples solely containing polymer standards and no cellular material 
produced only aqueous and organic phases.  The PHA-containing organic phase was 
removed and transferred to a 5 mm disposable NMR tube. The use of CDCl3 for 
extraction allows for direct 
1
H NMR analysis of the organic layer.  
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GC sample preparation was carried out in accordance with reported acid 
methanolysis procedures (Braunegg et al., 1978; Oehmen et al., 2005b). Equal volumes 
(0.7 mL) of acidified methanol (0.03% H2SO4) and chloroform were added to each 
sample to result in a total volume of 1.4 mL. These mixtures were vortexed and incubated 
at 100˚C for 2 h on a shaker table. After the samples had cooled, 0.4 mL of distilled water 
was added, followed by vortexing for 10 minutes. Following a phase separation time of 
20 minutes, the organic phase was transferred to a new vial for GC analysis. The total 
sample preparation time required for 
1
H NMR and GC analysis were respectively around 
2.15 and 2.5 h, and the 
1
H NMR method required less labor and materials.  
Environmental samples were prepared by repeated centrifugation and washing of 
1.5 mL aliquots. The centrifuged pellet was subsequently extracted/digested in 
accordance with 
1
H NMR and GC sample preparation procedures described above. 
 
2.6. Analytical Methods  
 
1
H NMR: A Jeol ECX-300 spectrometer (Jeol USA, Inc., Peabody, MA) with an 
Oxford 54-mm-bore magnet was used to obtain 300.53 MHz 
1
H NMR spectra in Fourier 
transform mode. The operating parameters consisted of a 13.43 μs pulse width at 90°, 
5636 Hz spectral width, 32 k data points, and 32 scans with a 1 s relaxation delay. 
Tetramethylsilane (TMS) at a concentration of 0.03% was used as an internal standard. 
Jeol Delta NMR Processing Software was used to analyze spectra. 
Gas Chromatography: An HP 6890 Series II gas chromatography system 
(Hewlett Packard, Wilmington, DE) equipped with a flame ionization detector (FID) and 
an autosampler was used in conjunction with an HP-INNOWax cross-linked polyethylene 
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glycol capillary column with dimensions of 30 m  0.25 mm ID  0.25 μm film 
thickness (Agilent Technologies, Wilmington, DE). A split injection ratio of 1:20 was 
used and argon at a flow rate of 3.8 mL/min was used as the carrier gas. Chromatography 
was performed using a temperature profile that consisted of an initial temperature of 60 
°C held constant for 4 min followed by a 15 °C/min increase to a final temperature of 250 
°C, which was again held constant for 5 minutes. The flame ionization detector and 
injection port temperatures were maintained at 250˚C.  HP-Chemstation software was 
used for peak integration and analysis. The lower initial temperature enabled clear 
separation between chloroform and PHA peaks. The retention times for HB and HV 
methyl esters were 9.55 and 10.31 minutes, respectively. A new calibration curve with 
PHA standards was constructed with every set of GC runs to account for variability and 
to ensure accuracy. Including an instrument cooling period, a total analysis time of 24 
minutes was required per sample.  
Fluorometry: A Nile blue A sulfate fluorescent dye solution was prepared at a 
concentration of 0.5 g/L ethanol (Kitamura and Doi, 1994). Approximately 150 μL of the 
dye solution was added to 50 μl of sample contained in wells of Microfluor 96-well black 
flat-bottom microtiter plates (Product No. 7805, Thermo Scientific, Hanover Park, IL). 
Black microtiter plates were used to reduce interference from background signals during 
fluorescence analyses. Fluorescence measurements were obtained using a Synergy™ 4 
Multi-Mode Microplate Reader with Hybrid Technology™ (BioTek, Winooski, 
VT).Respective excitation and emission wavelengths of 490 and 580 nm were used 
(Kitamura and Doi, 1994). The total amount of cells in each sample was correlated to the 
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fluorescence output readings using calculated dry cell weight data. Each relative 
fluorescence measurement was divided by the product of the sample volume (50 μl) and 
the dry cell weight (mg/ml) to yield specific fluorescence intensity. Relative PHA content 
determined by fluorescence staining was correlated to quantitative 
1
H NMR and GC data. 
 
3. Results 
3.1. PHB and PHBV Standards 
1
H NMR spectra were obtained for PHB and PHBV copolymer standards (Fig. 
4.1A and 4.1B). Three distinct peaks were observed for the HB fractions. A methyl HB 
doublet signal was observed at 1.28 ppm, a methylene doublet of quadruplet peak was 
detected at 2.54 ppm, and a multiplet methine peak was measured at 5.26 ppm. Two 
additional peaks corresponding to a methyl group at 0.90 ppm and a methine group at 
5.16 ppm were observed in the PHBV copolymer standards. These peaks correspond to 
those observed in previous studies (Doi et al., 1986; Jan et al., 1996). 
The PHB and P(HB-co-HV) 
1
H NMR calibration curves obtained using 
commercial standards are shown in Fig. 4.2A and 4.2B, respectively. The area of each 
PHA-specific signal was linearly proportional to polymer concentration. From the P(HB-
co-HV) data, the average copolymer composition was determined as 12.34% ± 0.52% 
HV by calculating the intensity ratio of the HB and HV methyl signals at 1.28 ppm and 
0.90 ppm, respectively. The vendor specified HV content in this standard is 12%. The 
ratio of methine peak areas at 5.2 and 5.16 ppm also gave similar values for HV content 
(Doi et al., 1986; Furrer et al., 2007). The CDCl3 peak at 7.25 ppm served as a reference 
signal, and the TMS peak at 0.00 ppm was used as an internal standard. The standards 
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used for calibration by NMR were also used to generate standard GC calibration curves 
following polymer derivatization. Both 
1
H NMR and GC/FID methods were used to 
quantify PHA standards at low concentrations of approximately 10 μg PHA/mL, which is 
consistent with reported PHA detection limit values for GC (Serafim et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1. 
1
H NMR spectra recorded using standard samples of (A) PHB polymer and (B) 
P(HB-co-HV) copolymer  
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Fig. 4.2. Standard 
1
H NMR
 
calibration curves established using standard samples of (A) 
PHB and (B) P(HB-co-HV). The standard deviation for each measurement was 
determined, but error bars are not visible because the standard deviation is smaller than 
the point markers on the graph.  All linear regression calibration lines had R
2
 >0.995 
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3.2.
 1
H NMR Correlation with GC and Fluorescence  
Measurements in Pure Cultures 
 
C. necator and A. vinelandii grew to high cell densities when cultured in the 
presence of simple sugars (Fig. 4.3). PHA synthesis in A. vinelandii was growth-
associated, while C. necator accumulated PHA in response to phosphate-limitation such 
that polymer content was observed to increase only after cultures reached stationary 
phase. Both of the strains exclusively accumulated PHB homopolymer with the provided 
carbon sources. The signals observed in 
1
H NMR spectra for C. necator and A. vinelandii 
(Fig. 4.4A and 4.4B) correspond closely to those obtained from standard PHB samples 
(Fig. 4.1). Since both strains accumulate PHA over time, it was expected that PHA 
content would increase during culture incubation. Thus, samples were periodically 
withdrawn and PHA content was measured using both the 
1
H NMR and GC/FID methods 
to simultaneously apply both analytical techniques to biomass containing varying 
polymer fractions for direct comparison.  
 
 
 
 
 
 
 
 
 
 
Fig. 4.3.  Sample growth curves for C. necator and A. vinelandii cells. 
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Fig. 4.4.  (A) 
1
H NMR spectrum of PHB polymer obtained from C. necator cells. (B) 
1
H 
NMR spectrum of PHB polymer obtained from A. vinelandii cells  
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 A strong correlation was observed between the 
1
H NMR and GC/FID data. Fig. 
4.5 shows PHA content data, as measured by both 
1
H NMR and GC/FID methods, from 
all replicate experiments performed with both strains. The slope of the linear regression 
line fitted through this data is 0.992 (forced through the origin) with an R
2
 value of 0.991. 
Thus, a near 1:1 correspondence of measured PHA content by both methods with only 
slight data scatter is observed demonstrating that the 
1
H NMR method has accuracy very 
similar to the traditional GC-based technique. Individually, for C. necator the regression 
line slope was 1.01 (R
2
 value of 0.998) indicating that the 
1
H NMR predicted slightly 
higher values of PHB content. Overall, the maximum observed PHB content (as 
measured by 
1
H NMR) was 68.6% (w/w) and 73.3% (w/w) in C. necator and A. 
vinelandii, respectively, which is consistent with reported values (Brandl et al., 1990; 
Holmes, 1985).   
 
 
 
 
 
 
 
 
 
Fig. 4.5. Correlation of 
1
H NMR and GC quantification data of PHB content for C. 
necator and A. vinelandii for all replications. A trendline was used to determine the 
regression coefficient as 0.992 (R
2
 = 0.991)   
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Fluorescence staining was used as an independent, qualitative indication of 
intracellular PHA content. As reported previously, fluorescence output from whole cell 
samples stained with Nile red is proportional to PHA concentrations (Page and Tenove, 
1996). The results in Fig. 4.6A and 4.6B verify this linear correlation between 
1
H NMR-
measured PHA and relative fluorescence intensity for the pure culture strains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6. PHB fraction as determined by GC and 
1
H NMR compared with the 
fluorescence intensity by Nile blue staining for (A) C. necator and (B) A. vinelandii 
cultures. For C. necator, the respective R
2
 values for 
1
H NMR and GC were determined 
as 0.979 and 0.983. Respective 
1
H NMR and GC R
2
 values of 0.772 and 0.799 were 
obtained in A. vinelandii samples. 
81 
 
3.3 PHA Analysis in Environmental Samples 
To verify wider relevance of our 
1
H NMR method, PHA analysis was performed 
for samples that (1) consist of a mixed microbial consortium, (2) contain different types 
of PHA, and (3) are known to contain high concentrations of background organic 
compounds that could compromise the integrity of 
1
H NMR PHA signals. Samples 
obtained from an agricultural waste treatment anaerobic digester were used to perform 
experiments based on the principles of EBPR processes to create an enriched population 
of PHA-accumulating microorganisms. In these experiments, aqueous PO4
3-
 
concentration fluctuated as expected – P uptake by microorganisms was observed when 
cultures were subjected to aerobic conditions and P release occurred during anaerobic 
conditions (data not shown). Although the composition of the microbial population has 
not been specifically determined, the rate of PO4
3- 
uptake increased with each cycle, 
indicating enrichment of a PAO population. The PHA content of a late-stage anaerobic 
sample was analyzed in triplicate to assess the applicability of 
1
H NMR for PHA analysis 
in environmental samples. An
1
H NMR spectrum of extracted polymer from the waste 
samples is presented as Fig. 4.7. The maximum PHA content was determined using 
1
H 
NMR as 0.299 ± 0.021 mg PHA/mL of effluent, and using GC/FID as 0.278 ± 0.038 mg 
PHA/ mL of effluent. The PHA copolymer structure was determined by 
1
H NMR using 
the HV- and HB-methyl peaks at 0.90 ppm and 1.28 and the HV- and HB-methine peaks 
at 5.16 ppm and 5.26 ppm. Approximately 12.98% ± 0.25% of the PHA copolymer was 
represented by PHV. This copolymer formation was expected, as the effluent contained 
significant levels of volatile fatty acids including acetate and propionate. 
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Fig. 4.7. 
1
H NMR spectrum for anaerobic digester sample. Peak overlap is observed at 
the 1.28 ppm doublet peak. This does not affect PHA quantification because the peaks at 
2.4 ppm and 5.26 ppm can each be integrated to determine PHA content  
 
4. Discussion 
In C. necator samples, 
1
H NMR consistently predicted slightly higher PHB 
content, as evidenced by a 
1
H NMR-GC/FID regression coefficient of 1.01. This is a 
likely result of the absence of a polymer derivatization step. Incomplete methanolysis of 
PHB in the GC/FID procedures could result in consistent underestimation (Jan et al., 
1995; Serafim et al., 2002). In the A. vinelandii samples, PHA content was slightly under-
predicted by 
1
H NMR such that the slope of the 
1
H NMR-GC/FID regression line was 
0.98 (Fig. 4.5). This discrepancy in 
1
H NMR-GC/FID correlation between different 
strains is presumably due to the composition of accumulated PHB. A. vinelandii can 
produce very high molecular weight PHB, ranging from 1 to 4 million Dalton (Chen and 
83 
 
Page, 1994).  In the methanolysis procedures, the molecular weight is a less relevant 
concern as the acid and heat treatment degrade the large polymer into smaller subunits. 
However, the high molecular weight polymer is not degraded in the 
1
H NMR method, 
which can result in incomplete extraction due to an increase in viscosity of the extracting 
solvent (CDCl3 in our case) and less efficient penetration into the biomass. Although the 
molecular weight was not determined in this study, the CDCl3 layer became highly 
viscous with larger concentrations of extracted PHA from A. vinelandii. When necessary, 
this issue was corrected for by using a lower amount of lyophilized cell mass. 
The Nile blue A sulfate staining method was demonstrated as insufficient for 
accurate quantitative PHA determination. Although useful as an independent qualitative 
measurement of PHA content, significant variability between analyses and differences in 
fluorescence intensities between cell types were observed with these procedures (Fig. 
4.6). In any case, fluorescence staining does not provide information on polymer 
composition. 
It is generally assumed that quantitative PHA analysis by 
1
H NMR requires 
purified PHA (Furrer et al., 2007). Such purification methods, as used by Jan et al. (1996) 
and Ivanova et al. (2009), were previously discussed and generally require several steps 
for extraction of PHA, evaporation of solvent, resuspension in CDCl3, and analysis by 
1
H 
NMR. These multiple steps make the overall process more time-consuming than 
GC/FID-based methods and compromise the accuracy of the method due to multiple 
sample handling steps (Furrer et al., 2007). The sample preparation method used in our 
study is simplified through the direct use of CDCl3 for both extraction and as the solvent 
for 
1
H NMR analysis. The time required for sample preparation was shortened and is less 
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than that of GC polymer derivatization procedures. Additionally, the 
1
H NMR 
spectrometer requires 73% less machine operation time in comparison to the gas 
chromatograph for sample analysis (about 6.5 minutes versus 24 minutes, per run) and 
may therefore be better suited for rapid analysis.  
There are several advantages to using 
1
H NMR instead of GC for PHA 
measurement. These include multiple peaks for cross-validation of results, the 
measurement of an intrinsic property instead of a derived parameter, and fewer 
instrument maintenance issues. Because the 
1
H NMR procedure does not require 
derivatization steps, the polymer may be retrieved, if necessary, and used for subsequent 
analyses. In contrast, the GC method leads to sample loss and incomplete derivatization 
could lead to inaccurate quantification. 
In the context of PHA analysis, 
1
H NMR may be considered more reliable than 
GC as the different structural components have unique chemical shifts that can be 
evaluated independently as a way of cross-checking quantified values. In contrast, PHA 
analysis with GC produces only one assessable peak per monomer type.  A lack of 
separation between HB and HV peaks or overlap with other compounds present in the 
sample can prevent accurate determination of the total PHA content and the ratio of 
monomer units (Serafim et al., 2002). Therefore, 
1
H NMR is more robust against signal 
overlap from sample contaminants. For example, an observable peak overlap at the 1.28 
ppm signal in Fig. 4.7 does not affect analysis due to multiple available peaks that can be 
used to cross-check and verify results. In samples containing P(HB-co-HV), the 
monomer fraction can be determined using multiple pairs of 
1
H NMR signals.  
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In regard to instrument maintenance issues, the GC method can lead to extensive 
column degradation over time if samples contain even trace amounts of water (Serafim et 
al., 2002). Consequently, additional drying steps are necessary in GC sample preparation 
to avoid variability between successive readings, particularly when analyzing a large 
number of samples. Also, frequent measurement of standards must be carried out for 
quality control. In contrast, moisture removal is not as crucial in the 
1
H NMR method as 
the H2O peak does not overlap with the component signals or cause maintenance issues. 
A proposed limiting factor to the use of NMR is that these machines are more 
expensive than GC instruments. However, NMR has applications in several areas of 
research that use 
1
H,
 13
C, 
31
P, or 
15
N nuclei for analysis. For example, 
13
C NMR can be 
used to analyze metabolic pathways and 
31
P NMR is useful for polyphosphate 
accumulation studies (Doi et al., 1989; Serafim et al., 2002). Accordingly, NMR facilities 
are fairly common at academic institutions and may be aptly utilized for PHA analysis at 
locations where such systems are available. 
 
5. Conclusions 
This study has outlined a consistent, simple, and efficient procedure for direct 
PHA quantification by 
1
H NMR using minimal extraction steps through direct use of 
CDCl3 in conjunction with sodium hypochlorite for extraction and analysis. Additionally, 
this study has verified that the accuracy of the 
1
H NMR method is equivalent to the GC-
based techniques. The results of this investigation demonstrate that 
1
H NMR analysis 
with a single-step extraction preparation method can be applied to routinely and 
accurately assess both PHA content and composition. The 
1
H NMR and GC 
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measurements were highly similar for every PHA type and source investigated in this 
study.  Specifically, the 
1
H NMR-based method was used for the determination of PHA 
content in full-strength agricultural waste samples, demonstrating that it is robust and 
unaffected by high levels of background impurities. Fewer extraction steps that 
minimized losses resulted in a reliable quantification method that required less time and 
materials.  
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CHAPTER 5 
 
AN INVESTIGATION OF PHASIN TRANSLOCATION AND PHA 
 
PRODUCTION IN ESCHERICHIA COLI
 
 
 
Abstract 
 
Background 
Product extraction and purification are commonly the most expensive aspects of 
cellular manufacturing processes. For example, polyhydroxyalkanoates (PHAs) are 
microbially-accumulated biodegradable plastics that hold potential to serve as an 
alternative to petrochemically-derived polymers. However, the widespread use of PHAs 
is limited by downstream processing costs. The purpose of this investigation is to use 
synthetic biological engineering techniques to investigate alternative methods for product 
recovery. Namely, secretion-based recovery holds potential to decrease production costs 
by minimizing mechanical and chemical solvent requirements.  
Results 
To carry out this project, a trial-and-error based approach using four signal 
peptides (HlyA, TorA, GeneIII, and PelB) was implemented to provide more comparative 
information on the functionality of targeting sequences and to investigate product 
secretion. Due to the binding interaction between phasin protein and PHA granules, a 
genetic fusion of phasin with signal peptides was explored to indirectly target PHAs for 
cellular export.  A library of biological parts and genetic devices was created for studying 
translocation of phasin and PHA. Recombinant production of PHAs was carried out in 
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three strains of E. coli and quantified using 
1
H NMR. Results suggest that the biological 
parts are functional and can be used for the production and recovery of cellular products. 
Conclusions  
The basic parts constructed for this study can now be implemented in further 
investigations on cellular product recovery. Additionally, composite BioBrick devices 
can now be more rigorously tested and evaluated to confirm phasin translocation and for 
further analysis of secretion-based PHA recovery. 
 
Background 
 PHAs are a family of biodegradable thermoplastics accumulated in more than 300 
microbial species [1]. In natural PHA-producers, the bioplastic material serves as a 
reserve of carbon, energy, and reducing power and accumulation occurs in response to a 
nutrient deficiency or environmental stress [1-4]. PHAs are materially comparable to 
conventional plastics, like polypropylene, but are fully biodegradable and renewable [5-
6]. Accordingly, PHAs are of interest as a sustainable source of non-petrochemically-
derived plastics for use in commercial and medical applications [4, 7].  
 Escherichia coli have been studied for recombinant PHA production due to fast 
growth rates and well-characterized genetic systems [8-9]. The natural inability of E. coli 
to regulate PHA accumulation offers enhanced control over the production mechanism, 
such as through the use of IPTG-regulated promoters [9]. Recombinant E. coli harboring 
bioplastic synthesis machinery from Cupriavidus necator can accumulate as much as 80-
90% polyhydroxybutyrate (PHB) [1, 10]. Each type of E. coli varies widely in its ability 
to accumulate bioplastics, so testing various strains is necessary [11]. In these organisms, 
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a nutrient deficiency or environmental stress is not required for production and instead 
accumulation is dependent on the concentration of acetyl-CoA precursor [1].  
 The high cost of PHA production is a frequently discussed and studied issue due 
to prohibitive effect on the commercial viability of bioplastics as a replacement for 
petroleum-based plastics [1, 5, 12-14]. The costs associated with PHA downstream 
processing represent as much as 50% of the total process expense [15]. Significant 
research has been carried out to develop improved recovery methods that require lower 
concentrations of chemical solvents or rely on mechanical disruption [16-17], although 
these techniques have fallen short of economic viability [17].  
 Strategies of further engineering E. coli have also been developed for improved 
PHA recovery. For example, PHA-producing E. coli transformed with the E-lysis gene of 
bacteriophage PhiX174 from plasmid pSH2 has been studied [18]. In this system, 
amorphous PHB is pushed out of the cell through an opening in the cell envelope formed 
by an E-lysis tunnel structure [18]. In another example, spontaneous autolysis was carried 
out in E. coli MG1655 harboring PHA biosynthesis genes from C. necator.  Up to 80% of 
the cells in culture released PHA granules, which were subsequently recovered by 
centrifuging and washing with distilled H2O [15]. While lysis-inducing methods are an 
improvement with reduced mechanical and solvent requirements, cellular death is not 
conducive to a continuous bioplastic production system. 
 In this study, a foundation for secretion-based recovery of bioplastics was 
investigated. Recovery of bioplastics using E. coli secretion mechanisms would eliminate 
the need for cell disruption by mechanical or chemical means, and could potentially lead 
to a continuous PHA production system. In gram-negative bacteria like E. coli, 
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compounds are exported via six major secretory pathways [19-22]. Recombinant proteins 
can be targeted to the type I and II secretory pathways through genetic fusion with signal 
peptide targeting sequences. Few guidelines exist for determining whether a given signal 
peptide will target a protein for translocation [23]. Accordingly, a trial-and-error based 
approach is useful for analyzing signal peptide responses with a protein of interest [23].  
PHAs are non-proteinaceous polyesters and therefore cannot be directly targeted 
for translocation by signal peptide fusion. Phasin is a low-molecular weight protein that 
plays a role in PHA granule formation by binding to the PHA granule surface [24-25]. 
Due to this binding interaction, this study sought to investigate a method for recovering 
bioplastics indirectly by creating genetic devices for translocation of phasin. A simple 
depiction of the design of this study is provided as Figure 5.1.  
 
 
 
 
 
 
 
 
 
Figure 5.1 Schematic for PHA cellular export. Phasin with attached signal peptide binds 
to the PHA granule surface and the PHA-phasin-signal peptide complex is targeted for 
secretion via either the type I or II secretory mechanisms. 
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Translocation of PHAs is more readily possible through sufficient optimization of 
granule size, which reportedly varies from 50 to 1,000 kDa based on the growth 
parameters and host strain [4]. One of the proposed functions of phasin is to increase the 
surface-to-volume ratio of granules so that higher accumulation levels can be achieved 
[25-27]. Therefore, the size of PHA granule can be decreased significantly through 
phasin overexpression [26]. Proteins of nearly 900 kDa have reportedly been secreted to 
the extracellular milieu by the type I secretory mechanism of gram-negative bacteria [28-
29]. 
Extracellular PHA deposition was observed in a mutated strain of Alcanivorax 
borkumensis SK2 [30]. This is the first account of extracellular PHA accumulation [31], 
although the mechanism of this system is unknown [30]. A defined secretion-based 
bioplastic recovery system would allow for optimization and incorporation of secretion 
mechanisms in organisms possessing advantageous characteristics, like E. coli or 
photoautotrophic PHA-producers R. sphaeroides and Synechocystis PCC 6803. To date, a 
secretion-based bioplastic recovery system has not been demonstrated.  
For phasin targeting, type I (HlyA), type II Sec-dependent (GeneIII and PelB), 
and type II TAT-dependent (TorA) signal peptides were investigated [23, 32-34]. The 
synthetic biological engineering concept of standardization was implemented into the 
design of this study due to the number of signal peptides and devices required. Genetic 
parts were constructed in accordance with the BioBrick and BioFusion technical 
standards [35-36].  This means that genetic devices are carried in BioBrick standard 
vectors and conform to rules concerning the presence of restriction enzymes [35]. The 
BioFusion standard was specifically used to create phasin and signal peptide parts 
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because this genetic fusion system is compatible with the original BioBrick standard [36-
37].  
The objectives of this study are to construct a library of biological devices for 
studying phasin and PHA translocation, to investigate and quantify bioplastic production 
in recombinant E. coli, and to test the functionality of genetic devices through analysis of 
phasin translocation. Movement of phasin or bioplastic to the periplasmic space would be 
advantageous due to simplified downstream processing requirements [33, 38]. 
Furthermore, successful translocation of phasin would be a novel achievement in itself, 
and would provide important preliminary information for further optimization of a PHA 
recovery mechanism. 
 
Materials and Methods 
 
Strains and Plasmids 
 
 Descriptions of strains and plasmids used to study PHA and phasin production 
and translocation are provided as Table 5.1. One Shot® Top10 Chemically-Competent E. 
coli (Invitrogen, Carlsbad, CA) were used as the host for assembly of BioBrick parts and 
devices. Completed BioBrick parts were then transformed in XL1-Blue or BL21-Gold 
(DE3) competent E. coli (Stratagene, La Jolla, CA). Plasmid pBHR68 harboring phaCAB 
from Ralstonia eutropha was used for recombinant PHA production [39]. Plasmids 
pLG575 and pK184HlyBD include the coding regions for proteins HlyB and HlyD [40-
41].  Plasmids pSB1AK3, pSB1A3, and pSB3K3 are BioBrick standard vectors for 
assembly and expression of BioBrick genetic devices [42].    
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Table 5.1. Strains and plasmids used in this study  
Strain/Plasmid Relevant Characteristics Reference  
E. coli Strains   
    TOP10 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 
nupG recA1 araD139 Δ(ara-leu)7697 galE15 galK16 
rpsL(Str
R) endA1 λ- 
Invitrogen 
    XL1-Blue 
endA1 gyrA96(nal
R
) thi-1 recA1 relA1 lac glnV44 F'[ 
::Tn10 proAB
+
 lacI
q
 Δ(lacZ)M15] hsdR17(rK- mK+) 
Stratagene 
    BL21-Gold                
(DE3) 
E. coli B F
–
 ompT hsdS(rB
– 
mB
–
) dcm
+
 Tet
R
 gal λ(DE3) 
endA Hte 
Stratagene 
   
Plasmids   
    pBHR68 pBluescript SK
-
 derivative, phbCAB, ColE1 origin, Amp
R
 [39] 
    pLG575 pACYC184 derivative, HlyBD, p15A origin, Cm
R
 [40] 
    pK184HlyBD pUC derivative, HlyBD genes, ColE1 origin, Kan
R
 [41] 
    pSB1AK3 High copy BioBrick vector, pMB1 origin, Amp
R
 and Kan
R
 [42] 
    pSB1A3 High copy BioBrick vector, pMB1 origin, Amp
R
 [42] 
    pSB3K3 Medium copy BioBrick standard vector, p15A origin, Kan
R
 [42] 
   
 
 
BioBrick Design and Assembly 
 
BioBrick parts required in this study include four signal peptides (HlyA, TorA, 
GeneIII, and PelB) and one protein coding region (phasin - PhaP1). Signal peptides were 
made through either synthetic design and construction (DNA 2.0, Menlo Park, CA) 
(HlyA, TorA) or by annealing forward and reverse oligonucleotides (GeneIII, OmpA, 
PelB) as described in Chapter 3.  The forward and reverse oligonucleotides of OmpA are 
given in Table 5.2, as this signal peptide was not described previously.  
A BioFusion-compatible phasin BioBrick was constructed by isolating PhaP1 
from the genomic DNA of R. eutropha by PCR with primers PhaP1FOR and PhaP1REV 
with the BioFusion prefix and suffix as overhanging ends, shown in Table 5.2. The 620 
bp PCR product was isolated by gel electrophoresis, digested with EcoRI and SpeI, and 
ligated into pSB3K3. A PstI site was removed from PhaP1 using a QuikChange II Site-
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Directed Mutagenesis Kit and the QuikChange® Primer Design Program (Stratagene, La 
Jolla, CA). The designed primers (g114t and g114t_antisense) for site-directed 
mutagenesis are given in Table 5.2. The protocol used is given in Appendix B.  Step-wise 
assembly of composite BioBrick devices was primarily carried out in pSB1AK3. 
Completed devices were subsequently ligated in pSB3K3 or pSB1A3.  
 
 
PHA Production in E. coli 
 
Glycerol stocks of E. coli harboring the pBHR68 plasmid were used to inoculate 5 
ml of LB supplemented with 50 μg/ml ampicillin. Other antibiotics were added as 
necessary when additional plasmids were present. Overnight cultures were used for 1:100 
v/v inoculations of 25 ml LB with appropriate antibiotics and 1% glucose [39]. An M9 
mineral salts medium with 0.2% yeast extract and 1.5% glucose was also tested for PHA 
growth [43]. For BL21-Gold (DE3) cells, sodium lactate was used instead of glucose as a 
Table 5.2. Oligonucleotides (prefix/suffix overhangs are bolded, restriction enzyme 
sites are underlined) 
Oligo/Primer  Description 5'-> 3'  Source 
OmpAFOR 
ctagaatgaaaaagacagctatcgcgattgcagtggcactggctggtttcgctaccgtagc
gcaggccgctccgaaaa 
This study 
OmpAREV 
ctagttttcggagcggcctgcgctacggtagcgaaaccagccagtgccactgcaatcgc
gatagctgtctttttcatt 
This study 
PhaP1FOR gaattcgcggccgcttctagaatgatcctcaccccggaaca This study 
PhaP1REV ctgcagcggccgctactagttcaggcagccgtcgtcttct This study 
g114t cgtcgagctgaaccttcaggtcgtcaagact This study 
g114t_antisense agtcttgacgacctgaaggttcagctcgacg This study 
pK184FOR aaagtcgaccaatacgcaaaccgcctctc This study 
pK184REV aaactcgagttacaggatcccacgctcat This study 
pK184FOR2 aaatctagacaatacgcaaaccgcctctc This study 
pK184REV2 aaactcgagttacaggatcccacgctcat This study 
pK184FOR3 aaagtcgaccaatacgcaaaccgcctctccccgcgcgttgg   This study 
pK184REV3 aaactcgagttacaggatcccacgctcatgtaaactttctgttacagac This study 
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carbon source [44]. IPTG was added to a final concentration of 0.1 mM when the OD600 
of cultures was 0.6-1.0 [43]. Stationary phase cells were harvested after 8-10 hours of 
growth by centrifugation at 4,000 x g for 20 minutes. PHA content was analyzed using 
either staining procedures or 
1
H NMR. 
Cells were stained with Nile blue A sulfate solution for PHA visualization. A 1% 
(w/v) solution of Nile blue A sulfate in ethanol [45] was used to stain heat-fixed smears 
for 10 minutes at 55˚C in a Coplin staining jar [46]. The stained smears were gently 
washed with ddH2O, followed by a washing with 8% acetic acid to remove residual stain. 
The slides were then carefully blotted dry and analyzed using a Nikon Eclipse Ti-U 
(Melville, NY) equipped with a G-2A green excitation longpass emission filter with an 
excitation wavelength range of 510-560 nm.  A Photometrics® CoolSNAP HQ
2
 high-
resolution camera and NIS-Elements AR software was used for image capturing and 
analysis.  
1
H NMR was used to quantify and identify PHAs. A detailed outline of sample 
preparation procedures was discussed in Chapter 4. Cells were lyophilized at -40˚C and 
33  10
-3
 mBar. Approximately 10 mg of cells were subjected to solvent dispersion with 
CDCl3 (0.03% TMS) and 5% (v/v) sodium hypochlorite for 2 hours at 37˚C. The CDCl3 
layer was separated by centrifugation at 1500 x g for 10 minutes and used for 
1
H NMR 
measurements. A Jeol ECX-300 spectrometer (Jeol USA, Inc., Peabody, MA) with an 
Oxford 54-mm-bore magnet was used for 300.53 MHz 
1
H NMR spectral analysis. 
Operating conditions are discussed in Chapter 4.  
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Cellular Fractionation and Western Blotting 
 
 Overnight cultures of E. coli BL21-Gold (DE3) harboring pLG575 and various 
composite BioBrick devices in pSB1A3 and were used to inoculate (1:100 v/v dilution) 
100 ml of LB media containing chloramphenicol (25 μg/ml) and ampicillin (50 μg/ml).  
The lysozyme/EDTA/osmotic shock and chloroform-based cellular fractionation 
procedures were previously discussed in Chapter 3, and more detailed instructions can 
also be found in Appendix B. Approximately 50 ml of supernatant was concentrated to 
0.5 ml using Centricon® YM-10 centrifugal filter devices (Millipore, Bellerica, MA). 
Proteins from fractioned samples were separated using precast 12% SDS-polyacrylamide 
tris-glycine gels (Jule Inc., Milford, CT). Electrophoresis operating conditions were used 
as specified by the manufacturer. Phasin immunoblotting was carried out using a PhaP1 
specific antibody [47, 48]. An Anti-Rabbit IgG HRP conjugated secondary antibody (Cat 
No.: W4011) was purchased from Promega (Madison, WI). Respective primary and 
secondary antibody concentrations of 1:50,000 v/v and 1:2,500 v/v were used. Western 
blotting procedures are discussed in Chapter 3 and in Appendix B.  
 
Results 
 
BioBrick Construction 
 
A complete list of individual and intermediate BioBrick parts is given as Table 
A.5, Appendix A. Separation of the PhaP1 PCR product is shown as Figure 5.2A. The 
PstI mutation in PhaP1 was successfully carried out and confirmed by sequencing 
analysis. The PhaP1 sequence is found in Table A.4, Appendix A. To facilitate an 
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efficient construction process, promoter and ribosome binding site BioBricks were made 
as composite parts.   
Four promoter/ribosome binding site combinations were constructed by either 
PCR of an existing composite BioBrick or by annealing forward and reverse 
oligonucleotides. These include lacI-regulated (BBa_R0010), lacI-regulated lambda pL 
hybrid (BBa_R0011), lambda cL-regulated (BBa_R0051), and tetR-repressible 
(BBa_R0040) promoters. The sequences of the promoter and ribosome binding site 
composites, as well as their respective part numbers as submitted to the Registry of 
Standard Biological Parts, are shown in Table A.3 in Appendix A.  
 
 
 
 
 
 
Figure 5.2 (A) Gel electrophoresis depicting PhaP1 gene isolation (600 bp) from R. 
eutropha by PCR; MW – Molecular Weight Marker (MassRuler™ DNA Ladder Mix, 
Fermentas, Glen Burnie, MD). (B) Example gel showing the difference in size between a 
control band (400 bp) of the PCR product prior to ligation and bands from colonies 
containing ligation products of phasin and double terminator (1031 bp); C – Control. 
 
 
Composite BioBrick parts were constructed primarily by cutting the vector with 
EcoRI and XbaI and the BioBrick harboring the coding region to be inserted with EcoRI 
and SpeI. A depiction of this assembly process is given as Appendix B. Successful 
ligation of parts was preliminarily detected by PCR with primers VF2 and VR [42] and 
observing an increased band size on a 1-2% agarose gel. Figure 5.2B shows an example 
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electrophoresis gel for detecting successful ligation of phasin with the double terminator 
sequence. Ligation of BioBrick parts is demonstrated by the difference in the size of 
bands between the marked controls and the PCR products. 
After completion, the six primary BioBrick devices regulated by the lac promoter 
(BBa_B0010), shown in Table 5.3, were removed from pSB1AK3 and ligated into 
pSB1A3 and pSB3K3. The pSB1A3 host plasmid was used for studies on phasin 
translocation because its origin of replication (pMB1) is compatible with the origin of 
replication of pLG575 (p15A).  Each lac-regulated signal peptide/PhaP1 composite in 
pSB1A3 was cotransformed with pLG575 into BL21-Gold (DE3). As mentioned in 
Chapter 3, pLG575 was cotransformed with all signal peptide-phasin constructs to 
maintain consistency, although the HlyBD proteins from pLG575 are only necessary for 
HlyA-targeted translocation. The pSB1A3 negative control without a coding region was 
constructed by XbaI and SpeI digestion and religation of compatible ends, as described in 
Chapter 3. Two additional composite devices were constructed for detection of binding of 
phasin to PHA granules. These parts were similarly constructed by fusion of the GFPuv 
cycle 3 variant (see Chapter 3) and phasin, but varied in the order of the two genes.  
Table 5.3. Description of BioBrick composite parts 
Designation Description 
  
PhaP1 Lac promoter, PhaP1 BioFusion BioBrick without signal peptide, pSB1A3 
PhaP1:HlyA PhaP1 C-terminal BioFusion with HlyA signal peptide, Lac promoter, pSB1A3 
TorA:PhaP1 PhaP1 N-terminal BioFusion with TorA signal peptide, Lac promoter, pSB1A3 
GeneIII:PhaP1 PhaP1 N-terminal  BioFusion with GeneIII signal peptide, Lac promoter, pSB1A3 
PelB:PhaP1 PhaP1 N-terminal  BioFusion  with PelB signal peptide, Lac promoter, pSB1A3 
OmpA:PhaP1 PhaP1 N-terminal  BioFusion  with OmpA signal peptide, Lac promoter, pSB1A3 
pSB1A3 pSB1A3 plasmid without insert coding region 
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Constructs were ligated into pSB3K3 to study potential PHA translocation due to 
compatibility between the origin of replications of pSB3K3 and pBHR68. The HlyA-
targeted PHA secretion system required additional consideration because this system also 
required the presence of the HlyBD genes from the pLG575 plasmid. Several designs 
were investigated to create this system.    
The first design for creating a HlyBD/PHA/pLG575 expression system involved 
the use of primers to isolate the HlyB and HlyD proteins from pK184HlyBD (primers 
pK184FOR and pK184REV) based on the plasmid sequence (see Appendix A). These 
primers included SalI and XhoI overhangs so that the PCR product could be digested and 
ligated into the pBHR68 plasmid. Two other primer sets (pK184FOR2 and pK184REV2) 
were designed with XbaI and XhoI overhangs so that the PCR product could be digested 
and ligated into the pBHR68, but so that phaCAB would be removed. PCR reactions were 
set up with either PfuUltra™ (Stratagene, La Jolla, CA) or Platinum® Taq (Invitrogen, 
Carlsbad, CA) high fidelity polymerases in several replicates to test varied reaction 
conditions. Specifically, different primer concentrations, annealing temperatures, reaction 
components, and template concentrations were tested in order to create near optimal 
conditions for obtaining the 4000 bp PCR product. A PCR product of an incorrect size 
(2000 bp) was obtained.  
As another attempt to create the HlyBD/PHA/pLG575 expression system, new 
primers (pK184FOR3 and pK184REV3) of increased length were designed to increase 
primer specificity. Similar negative results were observed. Finally, a restriction enzyme 
digestion was carried out with EcoRI. Based on the plasmid sequence, a 2263 bp 
fragment and a 3770 bp fragment should have been observed. Instead, one large band at 
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about 4500 bp was obtained, further suggesting that the received pK184HlyBD plasmid 
was incorrectly characterized and the exclusive use of pLG575 was justified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Diagram depicting the construction process of pBHR68:PhaP1:HlyA plasmid. 
 
 
The sequence of pLG575 was unavailable and could therefore not be readily used 
to design a combined PhaP1:HlyA fusion and HlyBD-encoding plasmid. Restriction 
mapping analysis of the pSB3K3 plasmid confirmed the presence of two XhoI restriction 
enzyme sites at positions 177 and 1020. PhaP1:HlyA in pSB3K3 was digested with 
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EcoRI and XhoI. The 1217 bp fragment was excised from an electrophoresis gel, 
purified, and used for ligation with pBHR68. The process of modifying the PhaP1:HlyA 
fusion and pBHR68 plasmids is depicted in Figure 5.3. The resulting plasmid, carrying 
both the PHA encoding genes and the PhaP1:HlyA fusion (designated as pBHR68-
PhaP1:HlyA), was cotransformed with pLG575 into E. coli (Fig. 5.4).  
 
 
 
 
 
 
 
Figure 5.4 An illustration of E. coli harboring pLG575 for HlyBD protein expression and 
pBHR68:PhaP1:HlyA for PHA production and PhaP1:HlyA BioFusion expression. 
 
 
PHA Production in E. coli 
 
 E. coli harboring the pBHR68 plasmid was studied for PHA accumulation. Cells 
were grown on either LB supplemented with 1% glucose, or in M9 Mineral Media with 
1.5% glucose and 0.2% yeast extract. There was not a significant detectable difference in 
PHA concentration between the two compositions. The LB composition was 
predominantly employed. The addition of IPTG was necessary because the phaCAB 
operon is regulated by the lacZ promoter from pBluescriptSK
-
 [39]. 
Figure 5.5 shows the results of Nile blue staining and fluorescence microscopic 
analysis with three different strains. Stained intracellular PHA is visible as bright, orange 
granules [46]. The negative control (Fig. 5.5A) was created by transforming Top10 cells 
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with only a BioBrick device encoding PhaP1. Top10 and XL1-Blue (Fig. 5.5B and 5.5C) 
consistently produced significant levels of PHA. BL21-Gold (DE3) did not accumulate 
significant PHA, especially when glucose was provided as the carbon source.  Sodium 
lactate was also tested as a carbon source for these cells [44]. While some improvement 
in PHA content was observed (Fig. 5.5D), Nile blue staining revealed that the number of 
cells accumulating significant levels of bioplastic was relatively low. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Nile blue staining of (A) Top10 E. coli without pBHR68 plasmid, (B) Top10 
with pBHR68, (C) XL1-Blue with pBHR68 and (D) BL21 (DE3) Gold with pBHR68. 
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A sample 
1
H NMR spectrum for XL1-Blue cells with pBHR68 is shown as Figure 
5.6.  The three observed peaks verify that accumulated bioplastic is solely formed as PHB 
with pBHR68 and glucose carbon source. The three characteristic peaks are magnified in 
the figure to show their unique splitting patterns. The methyl doublet signal is shown at 
1.28 ppm, a methylene doublet of quadruplet signal was detected at 2.54 ppm, and a 
multiplet methane peak corresponds to the signal at 5.26 ppm.  The peaks were integrated 
to obtain area values and determined bioplastic concentration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 
1
H NMR spectra for XL1-Blue cells. The three characteristic peaks of PHB 
are shown as magnified insets. 
 
 
Intracellular PHA was quantified using 
1
H NMR for the three different strains. 
Highest levels of PHA accumulation were consistently observed in XL1-Blue cells at 
around 55% of the cell dry weight. Top10 cells accumulated around 28-35% of cell dry 
weight as PHA. Measured BL21-Gold (DE3) PHA production was low and insignificant 
when measured by 
1
H NMR, despite efforts to increase accumulation by using sodium 
lactate as the primary carbon source. 
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Analysis of Phasin Translocation 
 
 E. coli BL21-Gold (DE3) harboring the constructs described in Table 5.3 were 
subjected to fractionation procedures (see Chapter 3 or Appendix B). As in the previous 
chapter, the chloroform-based procedure more effectively isolated cellular compartments. 
Measured activity of β-galactosidase was highest in the cytoplasmic fraction at 
approximately 80-90% of the total enzyme activity. The activity of alkaline phosphatase 
was highest in the periplasmic fraction at 65-75% of the total enzyme in all fractions.  
Proteins were separated using SDS-PAGE with 12% polyacrylamide gels and 
subjected to immunoblotting procedures.  The recommended primary antibody 
concentration was given as 1:4000 v/v [47-48]. However, experimentation was carried 
out using varied primary antibody dilutions on cytoplasmic samples from cells expressing 
unfused phasin. As shown in Figure 5.7, a near-optimal primary antibody concentration 
was determined as 1:50,000 v/v with a secondary antibody concentration of 1:2,500 v/v.  
 
 
 
 
 
 
 
 
 
Figure 5.7 Immunoblotting results with different dilutions of phasin primary antibody. 
The secondary antibody concentration was held constant at 1:2500 v/v. Phasin is visible 
as a 22 kDa band, and some nonspecific binding is observed at about 71 kDa and at 7.6 
kDa. 
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Protein fractions obtained using the chloroform procedure were analyzed by SDS-
PAGE and Western blotting. The polyacrylamide gels and corresponding immunoblots 
for each of the four signal peptide constructs are provided as Figure 5.8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 SDS polyacrylamide gels and corresponding immunoblots of subcellular 
fractions for (A) PhaP1:HlyA, (B) TorA:PhaP1, (C) GeneIII:PhaP1, and (D) PelB:PhaP1. 
C – cytoplasmic fraction, P – periplasmic fraction, M – membrane fraction, S – 
concentrated supernatant (media) fraction. The position of GFPuv bands varies from 
roughly 22-27 kDa, and this size discrepancy between bands is a result of fusion with 
signal peptides. 
 
For cells expressing the PhaP1:HlyA construct (Fig. 5.8A), a strong phasin band 
is observed at 22 kDa in the concentrated extracellular media. In these same samples, 
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minimal phasin is observed in the cytoplasmic fraction and a strong band is observed in 
the membrane fraction. This suggests that the expressed phasin is primarily targeted to 
the HlyA secretion machinery and translocated to the extracellular media, although the 
size of the secreted band is smaller than expected. The HlyA targeted secretion product 
should have the HlyA signal peptide attached to the phasin protein. Accordingly, the 
observed product is around 5.5 kDa smaller than expected.  
In analyzed TorA:PhaP1 samples, three distinct sizes of phasin were observed, 
which was consistent to the number and size differences of TorA targeted GFPuv (see 
Chapter 3). The strongest phasin band was observed in the membrane fraction, indicating 
that some of the targeted protein becomes entrapped in the inner cellular membrane. Like 
the TorA-targeted GFPuv, this could be partially due to the presence of positively-
charged arginine in the fusion scar. A periplasmic phasin band was observed, although 
the intensity of the unfused band was not significantly greater than that of the fused band, 
thereby indicating a potential issue with the fractionation procedures. Phasin was not 
translocated to the supernatant fraction with the TorA signal peptide. 
Phasin was primarily found in the membrane fraction when GeneIII was used for 
targeting (Fig. 5.8C). Some phasin is found in the supernatant, both in a fused and 
unfused form. Samples obtained from PelB:PhaP1 harboring cells contained significantly 
larger quantities of overall phasin. In particular, the membrane fraction had high levels of 
phasin that is apparent as a single smeared band. This could mean that the PelB targeted 
phasin is expressed at more significant levels, or it may be a result of procedural errors. 
The total amount of loaded protein, however, appears to be consistent with the total 
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amount of loaded protein for the other analyzed signal peptides. This was concluded by 
comparing the polyacrylamide gels for each of the signal peptides.  
 
Discussion 
 
 In this study, the BioBrick technical standard was used to efficiently construct a 
library of biological devices, including parts to analyze phasin translocation, the PHA-
phasin binding interaction, and PHA translocation. Many of the completed devices and 
individual parts were submitted to the Registry of Standard Biological Parts so that 
researchers can utilize these parts in creating new devices for targeting proteins for 
cellular export.  
 E. coli XL1-Blue cells harboring the pBHR68 plasmid were shown capable of 
accumulating as much as 55% of their cell dry weight as bioplastic. This was 
significantly higher than PHA accumulation observed in Top10 and BL21-Gold (DE3) E. 
coli at roughly 28% and 2%, respectively.  The inability of BL21-Gold (DE3) to 
accumulate significant levels of PHA demonstrates the variability between strains for 
PHA production. No PHA was detectable when glucose was provided as the carbon 
source. The PHA accumulation was slightly improved when sodium lactate was supplied, 
although the production levels remained suboptimal. This poor accumulation may be 
corrected for through media optimization studies or by using a different plasmid, 
although similar comparison studies with E. coli likewise noted significant variability 
between strains for PHA accumulation [11]. XL1-Blue was determined as a suitable 
candidate for PHA translocation studies, although this strain produces proteases, which 
may be dealt with if necessary by the addition of protease inhibitors. Lastly, the 
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developed 
1
H NMR procedure discussed in the previous chapter was shown to be useful 
for PHA quantification in E. coli.       
 The functionality of phasin BioBrick devices was suggested by SDS-PAGE 
analysis. Protein bands at 22 kDa corresponding to the size of phasin are observed [47]. 
The identity of the phasin protein was confirmed using a phasin-specific antibody. Using 
immunoblotting procedures, phasin translocation was analyzed. Preliminary results 
suggest some degree of phasin export. A significant phasin band was observed in the 
extracellular media when HlyA was used for targeting. A slight supernatant band was 
also observed for GeneIII-targeted phasin. For the TorA, GeneIII, and PelB signal 
peptides, significant levels of phasin were found in the membrane fractions. Periplasmic 
phasin was also observed when TorA was used for targeting.  
 There are a number of ways that phasin secretion or translocation could be 
improved. Among the many possibilities, other studies have investigated ways to further 
engineer E. coli to improve the efficiency of secretion mechanisms. SecYEG and TorD 
proteins are required for formation of secretion machinery in type II Sec- and TAT-
dependent machinery, respectively. It has been determined that overexpression of TorD 
leads to improved translocation efficiency [49]. To incorporate this concept into the 
biological systems constructed for this study, the SecYEG or TorD proteins could be 
constructed as BioBricks and combined with the signal peptide-phasin devices. This 
would not be necessary for the PhaP1:HlyA construct because HlyA operates by the type 
I pathway. Another way to potentially increase secretion efficiency is through 
optimization of factors like vector copy number and through the removal of the 
positively-charged arginine in the BioFusion scar. For example, the use of a high copy 
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number plasmid may lead to higher protein expression levels, but higher production may 
result in decreased secretion by overwhelming the secretion machinery.  The positively-
charged arginine could lead to issues with the phasin protein becoming entrapped in the 
inner membrane.  
 More information is still required to analyze the potential of the PHA-phasin-
signal peptide secretion-based recovery system, including the significance of the PHA-
phasin interaction. Three potential methods for analyzing this binding interaction involve 
GFP fusion, TEM imaging, and 
1
H NMR analysis. Genetic fusion of phasin with GFP 
would potentially allow for microscopic visualization of phasin bound to PHA granules. 
Parts were constructed in this study for this purpose. TEM imaging could be used to 
analyze the size of accumulated PHA granules. Successful overexpression and binding of 
phasin should result in a decreased PHA granule size [26]. Quantification of PHA content 
by 
1
H NMR in cells containing both pBHR68 and a phasin-expressing BioBrick may 
demonstrate PHA binding through increased PHA accumulation as a result of a 
maximized surface-to-volume ratio. 
 
Conclusions 
 
 In conclusion, a library of genetic parts and devices was completed using 
synthetic biological engineering concepts and BioBrick and BioFusion technical 
standards. These parts were tested for functionality, and current results suggest phasin 
expression and secretion in recombinant BL21-Gold (DE3). Phasin was observed in the 
supernatant when targeted using the HlyA and GeneIII signal peptides. The basic parts 
constructed for this study can now be implemented in other investigations of cellular 
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product recovery. Additionally, composite BioBrick devices can now be more rigorously 
tested and evaluated to confirm phasin translocation and for further analysis of secretion-
based PHA recovery. 
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CHAPTER 6 
 
GENERAL CONCLUSIONS 
 
 
The overall objective of this research was to use synthetic biological engineering 
principles to investigate mechanisms for cellular recovery. GFP, phasin, and PHAs all 
served as examples of cellularly manufactured compounds.  The aims of this study, as 
outlined in the introduction, were all addressed. The research completed provides 
significant evidence of BioBrick functionality and secretion of protein. 
 A library of genetic parts and devices was successfully constructed. This included 
signal peptides, GFP, and phasin BioBricks. In total, 58 BioBrick parts and intermediates 
were constructed. Additionally, a number of non-BioBrick genetic devices were created 
throughout the course of this study using molecular biology techniques. 
GFP was expressed and secreted to the extracellular medium of E. coli using 
signal peptide HlyA and a type I secretion mechanism. This is of significance as no 
previous study has utilized this system to recover GFP. Furthermore, GFP was 
translocated to the periplasmic space of E. coli using the TorA and GeneIII signal 
peptides. This specific study demonstrated that synthetic biological engineering standards 
could be applied to create functional secretion mechanisms.  
A consistent and efficient procedure was developed for PHA quantification using 
1
H NMR. After analyzing various procedures, it was determined that a validated 
1
H NMR 
procedure would be useful in assessing PHA content. This study demonstrated that the 
1
H 
NMR measurements were highly similar to those obtained using a traditional GC method, 
but that 
1
H NMR could be used to elucidate more detailed information about the 
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bioplastic composition. The developed method required fewer extraction steps and could 
be used to analyze complex environmental samples. This procedure was subsequently 
applied in studies on phasin translocation and PHA production to assess the ability of E. 
coli to produce bioplastics.  
A number of the constructed BioBricks were used to study phasin translocation. 
Although these experiments did not advance as significantly as the GFP translocation 
study, significant progress was made toward phasin and PHA recovery. First, XL1-Blue 
E. coli were engineered to accumulate 55% of their cell dry weight as PHA. Next, 
complex systems were constructed to study PHA secretion, such as the 
pBHR68:PhaP1:HlyA plasmid. Lastly, the current results of this study indicate that 
phasin is being expressed and is potentially being secreted to the extracellular media. 
This foundational work and evidence of BioBrick functionality allows further analysis 
and more rigorous testing of these systems. Additionally, all of the individual BioBrick 
parts constructed for these studies can be utilized directly by other researchers for 
studying secretion and translocation of various proteins. 
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CHAPTER 7  
 
FUTURE DIRECTIONS 
 
 
This section outlines specific ideas for improving cellular production and 
recovery. Efficient systems for optimized recovery would be important in engineering 
applications due to the potential beneficial effects on economic viability. There are 
several ways that cellular product recovery by secretion can be improved.  
The arginine found in the BioFusion ligation scar may be leading to protein 
entrapment in the inner membrane. This would likely be a result of the positive charge of 
the arginine amino acid. Accordingly, mutation of arginine to a neutral amino acid would 
potentially lead to a greater percentage of periplasmic or extracellular protein. Site-
directed mutagenesis could also be used to mutate the start codon in N-terminal fusion 
BioBricks to analyze whether higher levels of unfused GFP are observed as a result of 
aberrant translation of the start codon furthest from the ribosome binding site. Translation 
of unfused GFP may play a role in issues like higher levels of fluorescence observed in 
GeneIII:GFPuv than PelB:GFPuv. The second start codon could also be responsible for 
the observance of a strong unfused GFP band in cytoplasmic samples where a signal 
peptide fusion product should be predominant. 
 Secretion systems may also be improved through the overexpression of type II 
secretion machinery proteins, like TorD and SecYEG. A previous study demonstrated 
that TorD overexpression lead to more efficient GFP translocation [1]. The rationale 
behind this idea is that overexpression of these proteins leads to more secretion 
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machinery for protein to be transported through. These proteins could be inserted into 
BioBrick devices, or, if feasible, can be cotransformed with fusion devices into E. coli. 
Further studies could be carried out on the differences in fluorescence activity 
between the various signal peptide-GFP fusion constructs. Studies have stated that there 
is a fluorescence activity difference between Sec- and TAT-dependent GFP fusions, but 
the mechanism by which GFP activity is diminished has not been clearly outlined. It is 
possible that Sec-dependent GFP fusions lead to inactive GFP due to binding of Sec 
chaperone proteins that inhibit correct folding of GFP. There may also be issues that arise 
with GFP folding as a result of signal peptide fusion. For GFP:PhaP1 fusion constructs, 
the orientation of the fusion had a significant effect on the observed fluorescence. 
Specifically, GFP:PhaP1 fusion protein was fluorescent, whereas the PhaP1:GFP fusion 
protein was largely nonfluorescent. This suggests that studies on the crystal structure and 
folding of GFP could be worthwhile.   
 More work is necessary to analyze the PHA/phasin binding interaction. Previous 
studies have successfully demonstrated and exploited this interaction for other purposes.  
However, it is necessary to ensure that adequate levels of phasin expression and binding 
are observed in order for PHA translocation to be possible. This could be analyzed by 
TEM to detect a reduction in granule size, 
1
H NMR quantification to determine whether 
phasin expression leads to increased PHA accumulation by maximizing the surface-to-
volume ratio, or fluorescence investigations with constructed GFP-PhaP1 fusion devices. 
 The binding of phasin to PHA is critical to the success of this project design, and 
is also required in order to decrease PHA granule size to a point that is feasible for 
membrane translocation. In the type I secretion system, proteins as large as 900 kDa have 
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been successfully secreted. The internal diameter of the HlyA membrane channel is 
approximately 3.5 nm. The size of PHA granules would need to be reduced to a size 
sufficient for travel through this channel. 
BioBricks made for this study could be applied to secretion studies for different 
proteins. Product recovery is an important aspect of cellular manufacturing processes, so 
applying and optimizing the use of the constructed BioBricks in other systems would be 
of significant interest. Additionally, these devices could be moved to other organisms like 
Mycobacteria or cyanobacteria and tested for protein recovery [2-3]. As another 
alternative, a protein secretion device could be constructed to facilitate even more rapid 
analysis of additional proteins. This would entail designing a plasmid that contained a 
promoter, ribosome binding site, signal peptide, and terminator. Using specific restriction 
enzyme recognition sites, the device could be designed so that restriction enzyme 
digestion would create a space that a new protein could be inserted into. Accordingly, the 
design of a protein secretion device would reduce the amount of work required to create a 
new device to test for protein secretion. 
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APPENDIX A 
 
BIOBRICK PARTS AND SEQUENCES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A.1 Nucleotide sequences of signal peptides used in this study 
Signal Peptide  Nucleotide Sequence  Pathway  References 
HlyA  
ttagcctatggaagtcagggtgatcttaatccattaattaatgaaatcag
caaaatcattcagctgcaggtagcttcgatgttaaagaggaaagaact
gcagcttctttattgcagttgtccggtaatgccagtgatttttcatatggac
ggaactcaataaccctgaccacatcagcataataa 
 
 
Type I   [1-2] 
TorA  
atgaacaataacgatctctttcaggcatcacgtcggcgttttctggcaca
actcggcggcttaaccgtcgccgggatgctggggccgtcattgttaac
gccgcgacgtgcgactgcggcgcaagcg 
 
Type II (TAT)  [3-4] 
GeneIII  atgaaaaaattattattcgcaattcctttagttgttcctttctattctcactcc Type II (Sec)  [5-7] 
PelB  
atgaaatacctgctgccgaccgctgctgctggtctgctgctcctcgctg
cccagccggcgatggcc  
Type II (Sec)  [8-9] 
OmpA 
atgaaaaagacagctatcgcgattgcagtggcactggctggtttcgct
accgtagcgcaggccgctccgaaa 
 
Type II (Sec) [8] 
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Table A.2 Nucleotide sequences of some signal peptides found in E. 
coli that were not selected for use in this study [8] 
Signal Peptide  Nucleotide Sequence  Pathway  
LamB 
atgatgattactctgcgcaaacttcctctggcggttgccg
tcgcagcgggcgtaatgtctgctcaggcaatggct 
Type II (Sec)  
Lpp 
atgaaagctactaaactggtactgggcgcggtaatcctg
ggttctactctgctggcaggt 
Type II (Sec)  
MalE 
atgaaaataaaaacaggtgcacgcatcctcgcattatcc
gcattaacgacgatgatgttttccgcctcggctctcgcc 
Type II (Sec) 
OmpC 
atgaaagttaaagtactgtccctcctggtcccagctctgc
tggtagcaggcgcagcaaacgct 
Type II (Sec) 
OmpF 
atgatgaagcgcaatattctggcagtgatcgtccctgct
ctgttagtagcaggtactgcaaacgct 
Type II (Sec) 
PhoA 
atgaaacaaagcactattgcactggcactcttaccgttac
tgtttacccctgtgacaaaagcc 
 
Type II (Sec)   
PhoE 
atgaaaaagagcactctggcattagtggtgatgggcatt
gtggcatctgcatctgtacaggct 
Type II (Sec) 
StII 
atgaaaaagaatatcgcatttcttcttgcatctatgttcgttt
tttctattgctacaaatgcctatgca  
Type II (Sec) 
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Table A.3 Composite promoter and ribosome binding sites constructed in this study 
(ligation scar is underlined, RBS is bolded) 
Promoter/RBS Sequence Part Number 
  
 
Lac/BBa_B0034 
caatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggca
cgacaggtttcccgactggaaagcgggcagtgagcgcaacgcaattaatgtgag
ttagctcactcattaggcaccccaggctttacactttatgcttccggctcgtatgttgt
gtggaattgtgagcggataacaatttcacacatactagagaaagaggagaaa 
BBa_K208010 
Lambda pL Hybrid/ 
BBa_B0034 
aattgtgagcggataacaattgacattgtgagcggataacaagatactgagcacta
ctagagaaagaggagaaa 
BBa_K208011 
Lambda cL/ 
BBa_B0034 
taacaccgtgcgtgttgactattttacctctggcggtgataatggttgctactagaga
aagaggagaaa 
BBa_K208012 
Tet/BBa_B0034 
tccctatcagtgatagagattgacatccctatcagtgatagagatactgagcactac
tagagaaagaggagaaa 
BBa_K208013 
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Table A.4 Protein coding region nucleotide sequences 
Protein Sequence 
  
PhaP1 Unmutated 
ATGATCCTCACCCCGGAACAAGTTGCAGCAGCGCAAAAGGCCAAC
CTCGAAACGCTGTTCGGCCTGACCACCAAGGCGTTTGAAGGCGTCG
AAAAGCTCGTCGAGCTGAACCTGCAGGTCGTCAAGACTTCGTTCGC
AGAAGGCGTTGACAACGCCAAGAAGGCGCTGTCGGCCAAGGACGC
ACAGGAACTGCTGGCCATCCAGGCCGCAGCCGTGCAGCCGGTTGCC
GAAAAGACCCTGGCCTACACCCGCCACCTGTATGAAATCGCTTCGG
AAACCCAGAGCGAGTTCACCAAGGTAGCCGAGGCTCAACTGGCCG
AAGGCTCGAAGAACGTGCAAGCGCTGGTCGAGAACCTCGCCAAGA
ACGCCCCGGCCGGTTCGGAATCGACCGTGGCCATCGTGAAGTCGGC
GATCTCCGCTGCCAACAACGCCTACGAGTCGGTGCAGAAGGCGACC
AAGCAAGCGGTCGAAATCGCTGAAACCAACTTCCAGGCTGCGGCTA
CGGCTGCCACCAAGGCTGCCCAGCAAGCCAGCGCCACGGCCCGTAC
GGCCACGGCAAAGAAGACGACGGCTGCCTGA 
 
PhaP1 Mutated 
ATGATCCTCACCCCGGAACAAGTTGCAGCAGCGCAAAAGGCCAAC
CTCGAAACGCTGTTCGGCCTGACCACCAAGGCGTTTGAAGGCGTCG
AAAAGCTCGTCGAGCTGAACCTTCAGGTCGTCAAGACTTCGTTCGC
AGAAGGCGTTGACAACGCCAAGAAGGCGCTGTCGGCCAAGGACGC
ACAGGAACTGCTGGCCATCCAGGCCGCAGCCGTGCAGCCGGTTGCC
GAAAAGACCCTGGCCTACACCCGCCACCTGTATGAAATCGCTTCGG
AAACCCAGAGCGAGTTCACCAAGGTAGCCGAGGCTCAACTGGCCG
AAGGCTCGAAGAACGTGCAAGCGCTGGTCGAGAACCTCGCCAAGA
ACGCCCCGGCCGGTTCGGAATCGACCGTGGCCATCGTGAAGTCGGC
GATCTCCGCTGCCAACAACGCCTACGAGTCGGTGCAGAAGGCGACC
AAGCAAGCGGTCGAAATCGCTGAAACCAACTTCCAGGCTGCGGCTA
CGGCTGCCACCAAGGCTGCCCAGCAAGCCAGCGCCACGGCCCGTAC
GGCCACGGCAAAGAAGACGACGGCTGCCTGA 
 
GFPuv 
ATGGCTAGCAAAGGAGAAGAACTTTTCACTGGAGTTGTCCCAATTC
TTGTTGAATTAGATGGTGATGTTAATGGGCACAAATTTTCTGTCAGT
GGAGAGGGTGAAGGTGATGCTACATACGGAAAGCTTACCCTTAAAT
TTATTTGCACTACTGGAAAACTACCTGTTCCATGGCCAACACTTGTC
ACTACTTTCTCTTATGGTGTTCAATGCTTTTCCCGTTATCCGGATCAT
ATGAAACGGCATGACTTTTTCAAGAGTGCCATGCCCGAAGGTTATG
TACAGGAACGCACTATATCTTTCAAAGATGACGGGAACTACAAGAC
GCGTGCTGAAGTCAAGTTTGAAGGTGATACCCTTGTTAATCGTATC
GAGTTAAAAGGTATTGATTTTAAAGAAGATGGAAACATTCTCGGAC
ACAAACTCGAGTACAACTATAACTCACACAATGTATACATCACGGC
AGACAAACAAAAGAATGGAATCAAAGCTAACTTCAAAATTCGCCA
CAACATTGAAGATGGATCCGTTCAACTAGCAGACCATTATCAACAA
AATACTCCAATTGGCGATGGCCCTGTCCTTTTACCAGACAACCATTA
CCTGTCGACACAATCTGCCCTTTCGAAAGATCCCAACGAAAAGCGT
GACCACATGGTCCTTCTTGAGTTTGTAACTGCTGCTGGGATTACACA
TGGCATGGATGAGCTCTACAAATAA 
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Table A.5 Total list of individual, intermediate, and complete BioBrick parts 
Designation Description and Notes 
  
Individual Parts  
PhaP1 (M) Mutated phasin protein from C. necator, BioFusion compatibility, in pSB3K3 
GFPuv (G) Cycle-3 GFP mutant, BioFusion compatibility, in pSB1AK3 
HlyA (H) HlyA signal peptide, in pSB3K3 
TorA (T) TorA signal peptide, in pSB3K3 
GeneIII (G3) GeneIII signal peptide, in pSB3K3 
PelB (P) PelB signal peptide, in pSB1A2 
OmpA (O) OmpA signal peptide, in pSB1A2 
Terminator (Te) Double terminator, in pSB1AK3, from BioBrick Registry part BBa_B0015 
Silver GFP (S) BioFusion compatible GFP, from BioBrick Registry part BBa_125500 
  
Composite Promoter/RBS  
1 Tet Promoter/High efficiency ribosome binding site, parts BBa_R0040 and BBa_B0034, in pSB1AK3 
2 Lambda pL Hybrid/ High efficiency RBS, parts BBa_R0011 and BBa_B0034, in pSB1AK3 
3 Lambda cL/High efficiency RBS,  parts BBa_R0051 and BBa_B0034, in pSB1AK3 
4 Lac/ High efficiency RBS, parts BBa_R0010 and BBa_B0034, in pSB1AK3 
  
Intermediate Parts  
M/Te PhaP1 with terminator, in pSB1AK3 
G/Te GFPuv with terminator, in pSB1AK3 
H/Te HlyA signal peptide with terminator, in pSB1AK3 
M/H/Te PhaP1 with HlyA signal peptide and terminator, in pSB1AK3 
G/H/Te GFPuv with HlyA signal peptide and terminator, in pSB1AK3 
T/M/Te TorA signal peptide with PhaP1 and terminator, in pSB1AK3 
T/G/Te TorA signal peptide with GFPuv and terminator, in pSB1AK3 
G3/M/Te GeneIII signal peptide with PhaP1 and terminator, in pSB1AK3 
  
1
3
0
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Table A.5 continued  
Designation Description and Notes 
G3/G/Te GeneIII signal peptide with GFPuv and terminator, in pSB1AK3 
P/M/Te PelB signal peptide with PhaP1 and terminator, in pSB1AK3 
P/G/Te PelB signal peptide with GFPuv and terminator, in pSB1AK3 
O/M/Te OmpA signal peptide with PhaP1 and terminator, in pSB1AK3 
O/G/Te OmpA signal peptide with GFPuv and terminator, in pSB1AK3 
4/P Lac promoter/High efficiency ribosome binding site with PelB signal peptide, in pSB1AK3 
4/O Lac promoter/High efficiency ribosome binding site with OmpA signal peptide, in pSB1AK3 
G/M/Te GFPuv fusion with PhaP1, terminator, in pSB1AK3 
M/G/Te PhaP1 fusion with GFPuv, terminator, in pSB1AK3 
  
Intermediate Parts Not Used  
S/Te BioFusion compatible GFP with terminator, BBa_K125500 and BBa_B0015, in pSB1AK3 
P/S/Te PelB signal peptide with BioFusion compatible GFP and terminator,  in pSB1AK3 
O/S/Te OmpA signal peptide with BioFusion compatible GFP and terminator,  in pSB1AK3 
  
Composite Devices Not Studied  
1/M/Te Tet Promoter/High efficiency RBS with PhaP1 and terminator, in pSB1AK3 
2/M/Te Lambda pL Hybrid Promoter/High efficiency RBS with PhaP1 and terminator, in pSB1AK3 
3/M/Te Lambda cL Promoter/High efficiency RBS with PhaP1 and terminator, in pSB1AK3 
1/G3/M/Te Tet Promoter/High efficiency RBS with GeneIII, PhaP, and terminator, in pSB1AK3 
2/G3/M/Te Lambda pL Hybrid Promoter/High efficiency RBS with GeneIII, PhaP1, and terminator, in pSB1AK3 
3/G3/M/Te Lambda cL Promoter/High efficiency RBS with GeneIII, PhaP1, and terminator, in pSB1AK3 
1/P/M/Te Tet Promoter/High efficiency RBS with PelB, PhaP1, and terminator, in pSB1AK3 
2/P/M/Te Lambda pL Hybrid Promoter/High efficiency RBS with PelB, PhaP1, and terminator, in pSB1AK3 
3/P/M/Te Lambda cL Promoter/High efficiency RBS with PelB, PhaP1, and terminator, in pSB1AK3 
1/O/M/Te Tet Promoter/High efficiency RBS with OmpA, PhaP1, and terminator, in pSB1AK3 
2/O/M/Te Lambda pL Hybrid Promoter/High efficiency RBS with OmpA, PhaP1, and terminator, in pSB1AK3 
3/O/M/Te Lambda cL Promoter/High efficiency RBS with OmpA, PhaP1, and terminator, in pSB1AK3 
  
  
1
3
1
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Table A.5 continued  
Designation Description and Notes 
Complete Devices Used in Study  
4/M/Te PhaP1, Lac promoter, PhaP1 fusion BioBrick without signal peptide, pSB1A3 
4/M/H/Te PhaP1:HlyA, PhaP1 C-terminal fusion with HlyA signal peptide, Lac promoter, pSB1A3 
4/T/M /Te TorA:PhaP1, PhaP1 N-terminal fusion with TorA signal peptide, Lac promoter, pSB1A3 
4/G3/M /Te GeneIII:PhaP1, PhaP1 N-terminal  fusion with GeneIII signal peptide, Lac promoter, pSB1A3 
4/P/M /Te PelB:PhaP1; PhaP1 N-terminal  fusion  with PelB signal peptide, Lac promoter, pSB1A3 
4/O/M /Te OmpA:PhaP1, PhaP1 N-terminal  fusion  with OmpA signal peptide, Lac promoter, pSB1A3 
4/G/Te GFPuv, Lac promoter, GFPuv fusion BioBrick without signal peptide, pSB1A3 
4/G/H/Te GFPuv:HlyA, GFPuv C-terminal fusion with HlyA signal peptide, Lac promoter, pSB1A3 
4/T/G /Te TorA:GFPuv, GFPuv N-terminal fusion with TorA signal peptide, Lac promoter, pSB1A3 
4/G3/G /Te GeneIII:GFPuv, GFPuv N-terminal fusion with GeneIII signal peptide, Lac promoter, pSB1A3 
4/P/G /Te PelB:GFPuv, GFPuv N-terminal fusion with PelB signal peptide, Lac promoter, pSB1A3 
4/G/M/Te GFPuv:PhaP1, GFPuv fusion with PhaP1, Lac promoter, pSB1AK3 
4/M/G/Te PhaP1:GFPuv, PhaP1 fusion with GFPuv, Lac promoter, pSB1AK3 
  
Non-BioBrick Devices  
PhaP1, unmutated Phasin protein with original PstI site within the sequence 
PhaP1:HlyA:pBHR68 PhaP1 C-terminal BioFusion with HlyA signal peptide, Lac promoter, inserted into pBHR68 
pSB1A3 pSB1A3 plasmid modified so that there is no insert coding region 
  
1
3
2
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APPENDIX B 
 
PROTOCOLS, REAGENTS, AND MISCELLANEOUS 
 
 
Resuspending Oligonucleotides 
 
1.  Resuspend in TE Buffer (pH 7.0) 
 
  TE Buffer: 
10 mM Tris (add 4 ml of 500 mM stock)  
1 mM EDTA (add 0.4 ml of 500 mM stock) 
ddH2O to 200 ml 
Sterilize by autoclave 
 
  500 mM EDTA: 
   104 g EDTA into 500 ml ddH2O 
NaOH pellets to pH 8.0 
 
  Add appropriated volume designated on order sheet 
 
 
Annealing Oligonucleotides 
 
1. Mix equal (equimolar) volumes of complementary oligos  
2. Place in heatblock for 4 minutes (90-95˚C)  
3. Cool solution below 30°C slowly (Let sit at room temperature for  45 minutes) 
4. Store at 4˚C 
 
 
Phosphorylation with T4 Polynucleotide Kinase 
 
1. For 50 μl reaction add: 
 
X  µl ddH2O 
10  µl DNA at 1 µg/µl 
5  µl PNK Buffer 
5  µl ATP (10 mM) 
2  µl PNK  
50  µl TOTAL 
 
PCR 
 
For 20X master mix, add 330 µl ddH2O, 80 µl MgCl2, 50 µl Taq Buffer, 20 µl 10 mM 
dNTPs, 10 µl primer forward, 10 µl primer reverse, and 5 µl Taq polymerase 
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Restriction Enzyme Digestion 
 
1. For 25 μl reaction with Fast Digest Enzymes, add: 
 
19.5 µl DNA sample 
2.5  µl Fast Digest Buffer 
1.5  µl Enzyme 1 
1.5  µl Enzyme 2 
20  µl TOTAL 
 
2. Incubate at 37°C for 45-60 minutes in thermocycler 
 
 
Dephosphorylation using Phosphatases 
 
1. For FastAP: Add less than 10% of total volume 
a. Example - 1.5 μl to 20 μl total 
2. Incubate for 20 minutes at 37˚C 
3. Inactivate for 5 minutes at 75˚C 
 
 
Electrophoresis 
 
1. Gel Preparation:  
a. Weight out agarose 
i. For large gel, add 200 ml 1X TAE;  
ii. For small gel, add 50 ml 1X TAE .  
iii. For 1% gel, add 2 g agarose to large and 0.5 g agarose to small gel.  
iv. For 2% gel, add double the agarose.  
b. Heat in 20 second increments in microwave until boiling, stir carefully 
c. Let cool until comfortable to touch and add 1 μl of EtBR for every 10 μl 
of soln. 
d. After cooling period, pour into electrophoresis chamber and let solidify 
2. Gel Loading:  
a. Add 10 μl of DNA ladder (GeneRuler™ DNA Ladder Mix, ready-to-use) 
b. Add 6X loading dye (6X = sample volume + X; solve for X) 
3. Use Qiagen gel extraction kit to isolate DNA bands 
 
TAE (50X) Buffer: 
242 g Tris base to around 600 ml 
57.1 ml glacial acetic acid (1 mole) 
100 ml 0.5 M EDTA (pH 8.0) 
ddH2O to 1000 ml 
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Ligation Reaction 
 
1. Controls: Vector only sample without ligase, vector only sample with ligase. If 
the sample had been efficiently dephosphorylated, there should be few colonies. 
2. Calculations:  
 
(ng insert) = (bp insert/bp vector) X (Molar Ratio (4:1)) X (ng vector) 
 
 
X µl  DNA Vector 
X µl  DNA Insert 
1  µl Ligase 
1  µl Ligase Buffer 
X µl H2O 
10  µl TOTAL 
 
 
 
Transformation using Top10 
 
1. Thaw E. coli on ice, add 1-5 μl of DNA 
2. Let incubate for 30 minutes on ice 
3. Heat-shock for 30 seconds at 42°C without agitation 
4. Place vial on ice for 2 minutes 
5. Aseptically add 250 μl of S.O.C. media 
6. Cap and shake for 1 hr at 37°C 
7. Spread 200 μl on pre-warmed selective plate, incubate at 37°C overnight 
 
 
Transformation using BL21-Gold (DE3) 
 
1. Thaw E. coli on ice, separate 25-50 μl quantities into chilled 14-ml BD Falcon 
polypropylene tubes. 
2. Add 1-5 μl of DNA 
3. Let incubate for 30 minutes on ice 
4. Heat-shock for 30 seconds at 42°C without agitation 
5. Place vial on ice for 2 minutes 
6. Aseptically add 250-900 μl of S.O.C. media 
7. Cap and shake for 1 hr at 37°C 
8. Centrifuge at 200 x g for 3-5 minutes 
9. Spread 200 μl on pre-warmed selective plate, incubate at 37°C overnight 
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Transformation of XL1-Blue 
 
1. Pre-chill 14-ml BD Falcon polypropylene round-bottom tubes on ice. Preheat 
SOC medium to 42°C. 
2. Thaw the supercompetent cells on ice. When thawed, gently mix and aliquot 50 μl 
of cells into each pre-chilled tube. 
3. Add 1.7 μl of β-mercaptoethanol provided with this kit to each aliquot of cells. 
4. Swirl the contents of the tubes gently. Incubate the cells on ice for 10 minutes, 
swirling gently every 2 minutes. 
5. Add 0.1–50 ng of the experimental DNA to one aliquot of cells and add 1 μl of 
the pUC18 control DNA to the other aliquot. Swirl the tubes gently. 
6. Incubate the tubes on ice for 30 minutes. 
7. Heat-pulse the tubes in a 42°C water bath for 45 seconds. The duration of the heat 
pulse is critical for maximum efficiency. 
8. Incubate the tubes on ice for 2 minutes. 
9. Add 0.9 ml of preheated SOC medium and incubate the tubes at 37°C for 1 hour 
with shaking at 225–250 rpm. 
10. Plate ≤200 μl of the transformation mixture on LB agar plates containing the 
appropriate antibiotic  
11. 11. Incubate the plates at 37°C overnight (at least 17 hours for blue-white color 
screening).  
 
 
CTAB 
 
1. Prepare two water baths, one boiling and the other 68°C.    
2. Centrifuge the 12 ml tubes containing the 5 ml cultures in the large centrifuge at 
3,000 RPM for 20 min.  Discard supernatant.   
3. Resuspend cells in 200 μl of STET buffer. Transfer to 1.5 ml tubes. 
4. Add 10 μl (if older preparation) lysozyme (50 mg/ml) and incubate at room 
temperature for 5 min.   
5. Boil for 45 sec and centrifuge for 20 min at 13K RPM (or until pellet gets tight). 
6. Use a pipette tip to remove the pellet. Discard the pellet 
7. Add 5 μl RNase A (10 mg/ml) and incubate at 68°C for 10 minutes. 
8. Add 10 μl of 5% CTAB and incubate at room temperature for 3 min. 
9. Centrifuge for 5 min at 13K RPM, discard supernatant, and resuspend in 300 μl of 
1.2 M NaCl by vortexing. 
10. Add 750 μl of ethanol and centrifuge for 5 min at 13K RPM. 
11. Discard supernatant, rinse pellet very carefully in 80% ethanol, and let tubes dry 
upside down with caps open. 
 
138 
 
Site-Directed Mutagenesis 
 
1. Designing the Primers Needed: QuikChange® II Site-Directed Mutagenesis Kit 
(CAT#200523-5): 
2. Make the control: 
 
5 µl 10 X reaction buffer  
2  µl pWhitescript 4. 5-kb control 
plasmid (5 ng/μl) 
1.25  µl Oligo control primer #1 
1.25  µl Oligo control primer #2 
1 µl dNTP mix 
38.5 µl  ddH2O  
50  µl TOTAL 
 
3. Making the Samples: have concentrations of DNA at around 5 ng, 10 ng, 20 ng, 
and 50 ng (measure the concentrations using the nanodrop, calculate out how 
much volume of template would be required). Calculate how much of the primers 
would be needed (primers ordered from eurofins operon should have an original 
concentration around 100 μM) 
 
5 µl 10 X reaction buffer  
X  µl 
(5-50 ng) of dsDNA 
template 
X  µl (125 ng) Oligo primer #1 
X  µl (125 ng) Oligo primer #2 
1 µl dNTP mix 
X µl  ddH2O  
50  µl TOTAL 
 
4. Add 1 ul of PfuUltra HF DNA polymerase 
5. Add to ThermoCycler, use Mutagene Program  
a. Temp. 68°C for 1 min/kb plasmid (3kb=3 min, set for 5 minutes) 
b. Takes around 2 hr 
6. After PCR, added 1 μl of DpnI RE 
a. Gently/thoroughly mix, spin in microcentrifuge 1 minute 
b. Incubate at 37°C for 1 hr to digest parental supercoil dsDNA 
7. Transform 1 μl of DpnI-treated DNA into separate 50 μl aliquots of XL1-Blue 
supercompetent cells 
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Cellular Fractionation 
 
Overall 
 
a. Grow two 100 ml flasks of E. coli for each sample (14 vials total) until 
they reach OD 1.0-1.5 
b. Mix the two flasks that should both be nearly identical in OD 
c. Separate each flask of about 200 ml into 3-50 ml centrifuge tube (whole 
cells, protocol 1, and protocol 2) 
d. Centrifuge at 3500 x g for 15-30 min 
e. Save 100 ml of supernatant to concentrate and analyze 
f. Follow procedure 1 and 2  
 
1. Chloroform Method 
 
a. Wash the cells in 10 mL of 10 mM Tris-HCl, pH 8.0 buffer 
b. Centrifuge again 
c. Suspend pellet in smallest possible volume of 10 mM Tris-HCl buffer (do 
250 μl for 50 ml of culture) 
d. Add ice cold chloroform per OD600 of 1.0 gradually while swirling (add 20 
ul or 10 μl, about 2 drops) 
e. Mix suspension and incubate at room temp for 15 min.  
f. Add 800 μl of 10 mM Tris-HCl, pH 8.0, mix and centrifuge at 10000 x g 
for 10 min 
g. Recover supernatant using Pasteur pipette without disturbing shocked cell 
pellet and put fluid in test tube and place in ice 
h. Suspend shocked cells in 1 mL of 10 mM Tris-HCl, pH 8.0 
i. Add 1 μl of 0.1 M EDTA, pH 8.0 and 40 μL of lysozyme solution (50 mg 
per ml solution) 
j. Mix and incubate cells for 1 hr at room temp 
k. Add 10 μl of 0.1 M PMSF (dissolve 0.1742 g into 10 ml of 100% 
isopropanol). This step is necessary when using an E. coli strain 
containing proteases 
l. Sonicate for 15 seconds 
m. Centrifuge at 10000 x g for 10 min, recover supernatant 
 
2. Lysozyme/EDTA Method 
 
a. Resuspend pellet in 0.5 ml of periplasting buffer (20% sucrose, 1 mM 
EDTA, 30000 units/ml lysozyme) 
b. Incubate on ice for 5 minutes (in the 50 ml centrifuge tube) 
c. Add 0.5 ml of cold, pure water and mix, move to microcentrifuge tube 
d. Incubate on ice for 5 min 
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e. Centrifuge at 12000 x g for 2 min to remove spheroplasts 
f. Save supernatant 
g. Add 0.5 ml purified water to cytoplasmic fraction and let sit for 5 min at 
RT to make spheroplasts swell 
h. Sonicate in bursts to dissociate proteins 
i. Centrifuge at 12000 x g for 2 min, collect supernatant 
j. Add 0.5 ml of purified water and sonicate again 
k. Centrifuge at 12000 x g and collect supernatant  (pool with other 
supernatant) 
 
For 1 ml of periplasting buffer: 
588 μl of 34% (1 M) Sucrose 
2 μl of 500 mM EDTA 
12 μl of 50 mg/ml lysozyme solution 
398 μl ddH2O 
 
 
Alkaline Phosphatase Assay 
 
1. Prepare at 37°C in glass tube in order: 
a. 0.5M Tris-HCl, pH 9.0                     0.26 mL 
b. Sample                                              0.05 mL to 1.0 mL*** 
c. Water                                                Bring volume to 1.5 mL total 
d. 0.1M ρ-nitrophenylphosphate           0.26 mL  
2. Sample: cytoplasmic –0.05 to 0.26 ml; periplasmic – requires 0.05 to 1.0 ml 
3. Prepare a water control; incubate at 27°C until color formed (15-30  min),  record 
assay time, stop reaction by adding 1.0 mL of 2 M sodium carbonate 
4. For 96-well plates: 42 μl 0.5 M Tris, 20-50 μl sample (about 20 μl for cytoplasm, 
50 μl or periplasm, 35 μl for membrane fraction), 40 μl 5 mM PNPP, water to 200 
μl, 40 μl of 2 M sodium carbonate. 
 
 
β-galactosidase Assay 
 
1. Prepare at 37°C in glass tube in order 
a. 0.1M Na phosphate buffer, pH 7.5    0.9 mL 
b. Sample                                               0.06 – 0.3 mL *** 
c. Water                                                 Bring volume of 1.5 mL 
d. 5 mM ONPG                                     1.5 mL  
2. As a guideline use 0.1 mL for the cytoplasmic fraction and 0.5 mL fro the 
cytoplasmic fraction. However, if the color formation is inadequate or too intense, 
repeat the assay after making adjustments in the amounts or dilutions of the 
samples.  A410 values between 0.05 and 0.5 are optimal. 
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3. Prepare a control with water as sample.  The addition of ONPG starts the reaction. 
Incubate the reaction for 10 min (or longer if required at room temperature.  Stop 
the reaction with 1.0 mL of 2 M sodium carbonate.  Read the A410 values.  
4. For 96-well plates: 90 μl 0.1 M Na phosphate, 1-5 μl sample (about 2 μl for 
cytoplasm, 5 μl or periplasm, 4 μl for membrane fraction), 20 μl 5 mM ONPG, 
water to 200 μl, 50 μl of 2 M sodium carbonate. 
 
 
SDS-PAGE and Western Blotting 
 
5X SDS-PAGE Tank Buffer 
30.28 g Tris 
144.13 g Glycine 
10 g SDS (or 10 ml 10% SDS) 
ddH2O to 2L total volume 
 
Transfer Buffer  
3.03 g Tris 
14.4 g Glycine 
200 ml Methanol 
ddH2O to 1 L 
 
5X TBST Stock 
25 ml of 2 M Tris (pH 8.0) 
300 ml of 2.5 M NaCl 
2.5 ml of Tween-20 
ddH2O to 1 L 
 
1. SDS-PAGE 
a. Aliquot duplicate samples into 0.5 ml centrifuge tubes so that each 
contains around 40 μg of protein 
b. Add 3X Protein Loading Buffer 
c. Heat sample for 1 minute at 90-100°C 
d. Prepare gel by removing from package, breaking off the bottom piece with 
pliers, rinse the wells with 1 X SDS Tank buffer, and attach the gel to the 
electrophoresis unit 
e. Load gels in duplicate and run at 35 mAmps/gel until molecular weight 
marker reaches the bottom of the gel apparatus 
i. Maximum well volume is 50 μl 
f. Stain one gel using Coomassie Brilliant Blue for 15-45 minutes, 
depending on age of the solution 
g. Destain gel using destain solution and kimwipes to absorb excess dye. 
This process takes several hours. 
 
2. Transfer to PVDF Membrane 
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a. Place duplicate gel in dish containing transfer buffer and soak for 10 
minutes 
b. Cut 4 large and 4 small pieces of Whatman paper and soak in transfer 
buffer 
c. Cut 1 piece of PVDF membrane, soak in Methanol for 30 seconds, 
followed by soaking in transfer buffer for 3-5 minutes 
d. Arrange Trans-Blot Electrophoretic cell from anode (red-positive) to 
cathode (black-negative): 
i. Blot pad 
ii. 4 large pieces of Whatman  
iii. PVDF membrane 
iv. Gel 
v. 4 small pieces of Whatman (ensure that these pieces are only in 
contact with the gel and not with the PVDF membrane or large 
Whatman pieces 
vi. Blot pad 
e. Ensure that there are no air bubbles and that the membrane does not dry 
f. Run at 20-40 V/cell for about 1 hr.  
g. Carefully check to ensure transfer of prestain markers to PVDF membrane 
i. Do not move the gel or membrane in case the transfer is 
incomplete 
 
3. Western Blotting 
a. Block PVDF membrane in TBST 5% milk for 2-3 hours at room 
temperature  
i. Put membrane paper into small Tupperware, add 5% TBST milk 
solution, and shake. Do not let the membrane paper dry out 
b. Incubate with primary antibody in TBST 0.5% milk overnight at 4°C 
i. Move shaker to refrigerated room 
ii. Add the smallest volume of primary antibody solution possible 
c. Wash thoroughly with TBST 0.5% milk at least 3 times 
d. Incubate with secondary antibody in TBST 0.5% milk for 1-2 hours at 
room temperature 
e. Wash thoroughly with TBST 0.5% milk 
f. Wash thoroughly with TBST 
g. Drain blot 
h. Apply small amount of TMB substrate  
i. Add water to stop reaction once bands are visible 
j. Take pictures and do densitometric analysis immediately 
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BioBrick Assembly 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.1 BioBrick assembly process. Samples are cut with restriction enzymes. 
Fragments are purified using gel electrophoresis and gel extraction. Isolated DNA is 
mixed and ligated together. This process is repeated for each added part. 
 
 
pK184 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.1 Plasmid map of pK184-HlyBD plasmid 
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Supplemental Images 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.3 PHA extraction: (A) Separation of dispersion layers (B) Extracted PHA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.4 Color formation during assays of β-galactosidase and alkaline phosphatase 
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Figure B.5 Membrane fraction pellet after ultracentrifugation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.6 Setup for transfer of protein to PVDF membrane 
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